```
=> d his

     (FILE 'HOME' ENTERED AT 10:20:41 ON 24 SEP 2009)

     FILE 'REGISTRY' ENTERED AT 10:21:27 ON 24 SEP 2009
L1               STRUCTURE UPLOADED
L2             0 S L1
L3             5 S L1 FULL

=> d que l3 stat
L1               STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3             5 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED      22 ITERATIONS                          5 ANSWERS
SEARCH TIME: 00.00.01



=> s l3 and choline
          6905 CHOLINE
            30 CHOLINES
          6905 CHOLINE
                (CHOLINE OR CHOLINES)
L4             0 L3 AND CHOLINE

=> fil capl
FILE 'CAPLUS' ENTERED AT 10:22:47 ON 24 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
```

FILE COVERS 1907 - 24 Sep 2009 VOL 151 ISS 13
FILE LAST UPDATED: 23 Sep 2009 (20090923/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family
of databases have been updated to include new citing references
information. This enhancement may impact record import into
database management software. For additional information, refer
to NEWS 9.
'.FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s l3
L5 10 L3

=> d 1-10 bib abs hitstr

L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:207399 CAPLUS
DN 150:229703
TI Methods using non-peptide thrombopoietin (TPO) receptor agonists for
treating cardiovascular diseases/injuries
IN Erickson-Miller, Connie; Jenkins, Julian
PA USA
SO U.S. Pat. Appl. Publ., 21pp., Cont.-in-part of U.S. Ser. No. 554,811.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20090048318	A1	20090219	US 2008-256669	20081023
WO 2004096154	A2	20041111	WO 2004-US13468	20040429
WO 2004096154	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG

US 20070105824 A1 20070510 US 2006-554811 20061110

PRAI US 2003-466540P P 20030429
US 2003-471554P P 20030519
US 2003-495034P P 20030814
US 2004-549977P P 20040304
US 2004-554581P P 20040319
US 2004-556390P P 20040325
WO 2004-US13468 W 20040429
US 2006-554811 A2 20061110

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 150:229703

AB The invention discloses a method for treating cardiovascular disease/injury in a mammal (including a human) in need thereof, which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist.

IT 1033040-23-1 1033040-23-1D, salts
1117698-29-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-peptide TPO receptor agonists for treatment of cardiovascular diseases/injuries)

RN 1033040-23-1 CAPLUS

CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RN 1033040-23-1 CAPLUS

CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RN 1117698-29-9 CAPLUS

CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone], sodium salt (1:2) (CA INDEX NAME)



●2 Na

L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:93143 CAPLUS
DN 150:160099
TI Use of a thrombopoietin (TPO) cell cycle activator and a chemotherapeutic agent for the treatment of cancer
IN Erickson-Miller, Connie
PA USA
SO U.S. Pat. Appl. Publ., 22pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20090022814	A1	20090122	US 2008-166686	20080702
WO 2008101141	A2	20080821	WO 2008-US54046	20080215
WO 2008101141	A3	20081016		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2007-890236P	P	20070216	
US 2007-892552P	P	20070302	
US 2007-908205P	P	20070327	
US 2007-949347P	P	20070712	
US 2007-952289P	P	20070727	
US 2007-969192P	P	20070831	
US 2007-977216P	P	20071003	
WO 2008-US54046	A2	20080215	

AB The invention discloses a method for treating cancer in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a TPO cell cycle activator and a chemotherapeutic agent to such mammal.
IT 1033040-23-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TPO cell cycle activator and chemotherapeutic agent for treatment of cancer)

RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1338135 CAPLUS
DN 149:513836
TI Preparation of hydroxy-1-azo-derivatives as thrombopoietin mimetics for pharmaceutical use
IN Hayes, Jerome Francis
PA Smithkline Beecham Corp., USA
SO PCT Int. Appl., 15pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008134338	A1	20081106	WO 2008-US61225	20080423
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
PRAI US 2007-913601P	P	20070424		

OS MARPAT 149:513836
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Hydroxy-1-azo-benzene derivs. (I) as thrombopoietin (TPO) mimetics, wherein Z = COOH or tetrazol, are prepared by treating compound (II) (X = Cl, Br, I, Y = NO2, NH2, R = alkyl) with a boronic acid to form compds. (III) (Y = NH2, NO2, G = aryl), and then converting III to compds. I. Also invented are novel intermediates used in the novel processes. Also invented are pharmaceutical compns. comprising compds. made by novel processes.
IT 1033040-23-1P

RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxy-1-azo-derivs. as thrombopoietin mimetics for pharmaceutical use)
RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1138522 CAPLUS
DN 149:548251
TI Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor
AU Alper, Phil B.; Marsilje, Thomas H.; Mutnick, Daniel; Lu, Wenshuo; Chatterjee, Arnab; Roberts, Michael J.; He, Yun; Karanewsky, Donald S.; Chow, Donald; Lao, Jianmin; Gerken, Andrea; Tuntland, Tove; Liu, Bo; Chang, Jonathan; Gordon, Perry; Seidel, H. Martin; Tian, Shin-Shay
CS Genomics Institute of the Novartis Research Foundation (GNF), San Diego, CA, 92121, USA
SO Bioorganic & Medicinal Chemistry Letters (2008), 18(19), 5255-5258
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
AB A novel series of benzo[a]carbazole-based small mol. agonists of the thrombopoietin (Tpo) receptor is reported. Starting from a 3.4 μM high throughput screen hit, members of this series have been identified which are full agonists with functional potency <50 nM and oral bioavailability in mice.
IT 376592-42-6, Totrombopag
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discovery and biol. evaluation of benzo[a]carbazole-based small mol. agonists of thrombopoietin receptor)
RN 376592-42-6 CAPLUS
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1008939 CAPLUS
DN 149:282993
TI Thrombopoietin receptor agonist for treatment of cancer
IN Erickson-Miller, Connie Lynn
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008101141	A2	20080821	WO 2008-US54046	20080215
	WO 2008101141	A3	20081016		
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2008216106	A1	20080821	AU 2008-216106	20080215
	US 20090022814	A1	20090122	US 2008-166686	20080702
PRAI	US 2007-890236P	P	20070216		
	US 2007-892552P	P	20070302		
	US 2007-908205P	P	20070327		
	US 2007-949347P	P	20070712		
	US 2007-952289P	P	20070727		
	US 2007-969192P	P	20070831		
	US 2007-977216P	P	20071003		
	WO 2008-US54046	W	20080215		

OS MARPAT 149:282993
AB Invented is a method of treating cancer and pre-cancerous syndromes in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.
IT 1033040-23-1 1033040-23-1D, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thrombopoietin receptor agonist for treatment of cancer)

RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:735884 CAPLUS
DN 149:45179
TI TPO receptor agonist combination with other antiviral therapy for the treatment of viral diseases
IN Erickson-Miller, Connie L.; Jenkins, Julian; Theodore, Dickens
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 50pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008073864	A1	20080619	WO 2007-US86918	20071210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2006-869583P	P	20061212		

OS MARPAT 149:45179
AB The invention discloses a method for treating viral diseases, particularly hepatitis C, in a human, in need thereof which comprises the administration of a combination of therapeutically active agents selected from a TPO receptor agonist and an antiviral therapy selected from an α-interferon, ribavirin, a ribavirin analog, and an HCV antiviral to such human.
IT 1033040-23-1 1033040-23-1D, salts or esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TPO receptor agonist combination with other antiviral therapy for treatment of viral diseases)
RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:435850 CAPLUS
DN 146:428547
TI Non-peptide thrombopoietin receptor agonist for the preservation of platelet efficacy during storage
IN Erickson-Miller, Connie Lynn
PA SmithKline Beecham Corporation, USA
SO PCT Int. Appl., 34pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2007044982 A2 20070419 WO 2006-US40494 20061013
WO 2007044982 A3 20090430
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
EP 1942906 A2 20080716 EP 2006-826085 20061013
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS
JP 2009511603 T 20090319 JP 2008-535784 20061013
US 20080286865 A1 20081120 US 2008-89978 20080411
PRAI US 2005-726249P P 20051013
WO 2006-US40494 W 20061013
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 146:428547
AB This invention relates to method for the preservation of human platelet lifespan and/or efficacy during storage which comprises the addition of an effective amount of a non-peptide TPO receptor agonists to a storage solution containing human platelets.
IT 376592-42-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-peptide thrombopoietin receptor agonist for preservation of platelet efficacy during storage)
RN 376592-42-6 CAPLUS
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)



L5 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:405369 CAPLUS
DN 142:463730
TI Preparation of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one choline salt
IN Brook, Christopher S.; Ping, Li-Jen J.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005041867	A2	20050512	WO 2004-US34944	20041021
	WO 2005041867	A3	20051013		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004285462	A1	20050512	AU 2004-285462	20041021
	CA 2543216	A1	20050512	CA 2004-2543216	20041021
	EP 1684748	A2	20060802	EP 2004-796011	20041021
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004015704	A	20061219	BR 2004-15704	20041021
	CN 1897937	A	20070117	CN 2004-80038488	20041021
	JP 2007509159	T	20070412	JP 2006-536801	20041021
	ZA 2006002901	A	20080227	ZA 2006-2901	20060410
	IN 2006DN02031	A	20070622	IN 2006-DN2031	20060413
	US 20070072922	A1	20070329	US 2006-576411	20060420
	MX 2006004483	A	20060620	MX 2006-4483	20060421
	KR 2006095761	A	20060901	KR 2006-707688	20060421
	NO 2006002111	A	20060718	NO 2006-2111	20060511
PRAI	US 2003-513481P	P	20031022		
	WO 2004-US34944	W	20041021		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:463730

GI



I

AB An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one (I), is prepared by treating 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one with choline hydroxide. The compound I is useful as an agonist of thrombopoietin receptor in enhancing platelet production, particularly in the treatment of thrombocytopenia. A tablet and injectable parenteral composition containing I are described.

IT 851606-62-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrozol-3-one choline salt as thrombopoietin receptor agonist)

RN 851606-62-7 CAPLUS

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl-3H-pyrazol-3-one (1:1) (CA INDEX NAME)

CM 1

CRN 851606-61-6
CMF C25 H21 N8 O2



CM 2

CRN 62-49-7
CMF C5 H14 N O

IT 376592-42-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrozol-3-one choline salt as thrombopoietin receptor agonist)

RN 376592-42-6 CAPLUS

CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:965013 CAPLUS
DN 141:406144
TI Methods for treating degenerative diseases/injuries using nonpeptide thrombopoietin receptor agonists
IN Erickson-Miller, Connie L.; Jenkins, Julian
PA SmithKline Beecham Corporation, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096154	A2	20041111	WO 2004-US13468	20040429
	WO 2004096154	A3	20050331		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1622609	A2	20060208	EP 2004-760459	20040429
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006525352	T	20061109	JP 2006-514185	20040429
	US 20070105824	A1	20070510	US 2006-554811	20061110
	US 20090048318	A1	20090219	US 2008-256669	20081023
	US 20090143453	A1	20090604	US 2009-366968	20090206
PRAI	US 2003-466540P	P	20030429		
	US 2003-471554P	P	20030519		
	US 2003-495034P	P	20030814		
	US 2004-549977P	P	20040304		
	US 2004-554581P	P	20040319		
	US 2004-556390P	P	20040325		
	WO 2004-US13468	W	20040429		
	US 2006-554811	A2	20061110		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:406144
AB Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal. An injectable form for administering the present invention is produced by stirring 1.5 % by weight of 4'-[N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino]-3'-hydroxy biphenyl-3-carboxylic acid in 10 % by volume propylene glycol in water.
IT 376592-42-6
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as nonpeptide TPO receptor agonist; nonpeptide thrombopoietin receptor agonists for treatment of degenerative diseases/injuries)
RN 376592-42-6 CAPLUS
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:868162 CAPLUS
DN 136:5987
TI Thrombopoietin mimetics
IN Duffy, Kevin J.; Erickson-Miller, Connie L.; Eppley, Daniel F.; Jenkins, Julian; Luengo, Juan I.; Liu, Nannan; Price, Alan T.; Shaw, Antony N.; Visonneau, Sophie; Wiggall, Kenneth
PA SmithKline Beecham Corporation, USA; Glaxo Group Limited
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001089457	A2	20011129	WO 2001-US16863	20010524
	WO 2001089457	A3	20020307		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2411468	A1	20011129	CA 2001-2411468	20010524
	CA 2411468	C	20080415		
	AU 2001074938	A	20011203	AU 2001-74938	20010524
	EP 1294378	A2	20030326	EP 2001-941599	20010524
	EP 1294378	B1	20071003		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011116	A	20030408	BR 2001-11116	20010524
	CN 1444477	A	20030924	CN 2001-813340	20010524
	CN 100423721	C	20081008		
	HU 2003002257	A2	20031028	HU 2003-2257	20010524
	HU 2003002257	A3	20070328		
	JP 2003534257	T	20031118	JP 2001-585703	20010524
	JP 3813875	B2	20060823		
	NZ 522474	A	20041029	NZ 2001-522474	20010524
	NZ 533308	A	20051028	NZ 2001-533308	20010524
	AU 2001274938	B2	20060119	AU 2001-274938	20010524
	AT 374772	T	20071015	AT 2001-941599	20010524
	EP 1864981	A1	20071212	EP 2007-112105	20010524
	EP 1864981	B1	20090722		

	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, SI				
EP	1889838	A1	20080220	EP 2007-112106	20010524
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, SI				
ES	2294000	T3	20080401	ES 2001-941599	20010524
CN	101343250	A	20090114	CN 2008-10129758	20010524
CN	101343251	A	20090114	CN 2008-10129759	20010524
CN	101342169	A	20090114	CN 2008-10129760	20010524
IL	152988	A	20090211	IL 2001-152988	20010524
NO	2002005566	A	20030122	NO 2002-5566	20021120
NO	324246	B1	20070917		
IN	2002MN01666	A	20041211	IN 2002-MN1666	20021121
KR	798568	B1	20080128	KR 2002-715869	20021123
ZA	2002009561	A	20031020	ZA 2002-9561	20021125
MX	2002011621	A	20040517	MX 2002-11621	20021125
US	20040019190	A1	20040129	US 2003-296688	20030703
US	7160870	B2	20070109		
HK	1055561	A1	20080411	HK 2003-106428	20030909
JP	2006137764	A	20060601	JP 2005-353686	20051207
US	20070179192	A1	20070802	US 2006-558071	20061109
US	7335649	B2	20080226		
US	20070129338	A1	20070607	US 2007-620260	20070105
US	7332481	B2	20080219		
US	20080090996	A1	20080417	US 2007-650688	20070108
US	7439342	B2	20081021		
US	20080090787	A1	20080417	US 2007-650838	20070108
US	7452874	B2	20081118		
US	20080214640	A1	20080904	US 2007-650651	20070108
US	7473686	B2	20090106		
KR	2007087255	A	20070827	KR 2007-718036	20070806
KR	847172	B1	20080717		
US	20090155203	A1	20090618	US 2008-141397	20080618
US	20090176973	A1	20090709	US 2008-141379	20080618
US	20090176746	A1	20090709	US 2008-141422	20080618
PRAI US	2000-207084P	P	20000525		
US	2000-228929P	P	20000830		
CN	2001-813340	A3	20010524		
EP	2001-941599	A3	20010524		
JP	2001-585703	A3	20010524		
WO	2001-US16863	W	20010524		
KR	2002-715869	A3	20021123		
US	2003-296688	A1	20030703		
US	2007-650651	A1	20070108		
US	2007-650688	A1	20070108		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 136:5987

GI



I

AB Pyrazolylidenehydrazino compds. such as I were prepared as thrombopoietin mimetics. Thus, I was prepared in 5 steps, the last of which involved

reaction of 4-amino-3'-hydroxy-3-biphenylcarboxylic acid hydrochloride with 1-(3,4-dimethylphenyl)-3-methyl-3-pyrazolin-5-one.
1T 376592-42-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
((pyrazolylidenehydrazino)phenol derivs. as thrombopoietin mimetics)
RN 376592-42-6 CAPLUS
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)



OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

=> => d que l9 stat
L6 36 SEA FILE=CAPLUS ABB=ON PLU=ON ("BROOK CHRIS"/AU OR "BROOK CHRIS B"/AU OR "BROOK CHRISTOPHER S"/AU OR "BROOK CHRISTOPHER W"/AU)
L7 11 SEA FILE=CAPLUS ABB=ON PLU=ON ("PING LI JEN"/AU OR "PING LI JEN J"/AU)
L8 45 SEA FILE=CAPLUS ABB=ON PLU=ON L6 OR L7
L9 1 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND CHOLINE

=> d bib abs

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:405369 CAPLUS
DN 142:463730
TI Preparation of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one choline salt
IN Brook, Christopher S.; Ping, Li-Jen J.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005041867	A2	20050512	WO 2004-US34944	20041021
WO 2005041867	A3	20051013		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2004285462	A1	20050512	AU 2004-285462	20041021
CA	2543216	A1	20050512	CA 2004-2543216	20041021
EP	1684748	A2	20060802	EP 2004-796011	20041021
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR	2004015704	A	20061219	BR 2004-15704	20041021
CN	1897937	A	20070117	CN 2004-80038488	20041021
JP	2007509159	T	20070412	JP 2006-536801	20041021
ZA	2006002901	A	20080227	ZA 2006-2901	20060410
IN	2006DN02031	A	20070622	IN 2006-DN2031	20060413
US	20070072922	A1	20070329	US 2006-576411	20060420
MX	2006004483	A	20060620	MX 2006-4483	20060421
KR	2006095761	A	20060901	KR 2006-707688	20060421
NO	2006002111	A	20060718	NO 2006-2111	20060511
PRAI US	2003-513481P	P	20031022		
	WO 2004-US34944	W	20041021		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 142:463730
GI



I

AB An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one (I), is prepared by treating 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one with choline hydroxide. The compound I is useful as an agonist of thrombopoietin receptor in enhancing platelet production, particularly in the treatment of thrombocytopenia. A tablet and injectable parenteral composition containing I are described.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (thrombopoietin or tpo) and choline
3471 THROMBOPOIETIN
29 THROMBOPOIETINS
3474 THROMBOPOIETIN
(THROMBOPOIETIN OR THROMBOPOIETINS)
5163 TPO
182 TPOS
5263 TPO
(TPO OR TPOS)

```
        54888 CHOLINE
          273 CHOLINES
        54991 CHOLINE
              (CHOLINE OR CHOLINES)
L10        11 (THROMBOPOIETIN OR TPO) AND CHOLINE

=> s l10 not l9
L11        10 L10 NOT L9

=> d 1-10 bib abs kwic

L11  ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2007:1064527  CAPLUS
DN   147:371991
TI   Preparation and storage of stable, biologically active materials
IN   Manders, Ernest K.; Manders, Christian D.
PA   Promethean Lifesciences, Inc., USA
SO   PCT Int. Appl., 25 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ------------------  -----  ----------  -----------------------  --------
PI   WO 2007106582       A2     20070920    WO 2007-US6592           20070315
     WO 2007106582       A3     20071122
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
             KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN,
             MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
          RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRAI US 2006-782420P     P      20060315
AB   The invention involves taking a base material such as allografts,
     xenografts, polymers, metals, and ceramics and combining it with a biol.
     active agent, such as proteins, cytokines, growth factors, and enzymes
     after which it is irradiated with ionizing radiation to sterilize and
     stabilize the material.  The resulting biol. active material may then be
     stored at ambient temperature while maintaining its biol. activity and the
     structural integrity of the base material.  The invention is particularly
     useful for eliciting desired biol. responses in human and animal medicine,
     and in certain industrial applications.
IT   50-06-6, Phenobarbital, biological studies  50-24-8, Prednisolone
     50-33-9, Phenylbutazone, biological studies  50-48-6, Amitriptyline
     50-53-3, Chlorpromazine, biological studies  50-55-5, Reserpine
     50-56-6, Oxytocin, biological studies  50-78-2, Aspirin  51-06-9,
     Procainamide  51-43-4, Epinephrine  51-55-8, Atropine, biological
     studies  57-42-1, Meperidine  57-47-6, Physostigmine  57-53-4,
     Meprobamate  58-22-0, Testosterone  58-39-9, Perphenazine  58-55-9,
     Theophylline, biological studies  58-73-1, Diphenhydramine  58-74-2,
     Papaverine  58-94-6, Chlorothiazide  59-42-7, Phenylephrine  59-47-2,
     Mephenesin  59-99-4, Neostigmine  69-23-8, Fluphenazine  72-69-5,
     Nortriptyline  73-48-3, Bendroflumethiazide  76-99-3, Methadone
     77-21-4, Glutethimide  91-81-6, Tripelennamine  103-90-2, Acetaminophen
     146-54-3, Triflupromazine  148-56-1, Flumethiazide  299-42-3, Ephedrine
```

302-17-0, Chloral hydrate 409-21-2, Silicon carbide, biological studies 469-62-5, Propoxyphene 523-87-5, Dimenhydrinate 525-66-6, Propranolol 1302-88-1, Cordierite 1314-23-4, Zirconia, biological studies 1344-28-1, Alumina, biological studies 1398-61-4, Chitin 5818-17-7, Methantheline 7440-06-4, Platinum, biological studies 7440-09-7, Potassium, biological studies 7440-22-4, Silver, biological studies 7440-32-6, Titanium, biological studies 7440-57-5, Gold, biological studies 7632-10-2, Deoxyephedrine 9000-69-5, Pectin 9000-83-3, ATPase 9000-86-6, Alanine transaminase 9000-92-4, Amylase 9000-96-8, Arginase 9000-97-9 9001-03-0, Carbonic anhydrase 9001-05-2, Catalase 9001-06-3, Chitinase 9001-08-5, Cholinesterase 9001-15-4, Creatine kinase 9001-16-5, Cytochrome c oxidase 9001-25-6, Blood-coagulation factor VII 9001-28-9, Factor IX 9001-29-0, Blood-coagulation factor X 9001-30-3, Blood-coagulation factor XII 9001-37-0, Glucose oxidase 9001-42-7, Maltase 9001-48-3, Glutathione reductase 9001-50-7, Glyceraldehyde 3-phosphate dehydrogenase 9001-51-8, Hexokinase 9001-52-9, Fructose bisphosphatase 9001-54-1, Hyaluronidase 9001-58-5, Isocitrate dehydrogenase 9001-60-9, Lactate dehydrogenase 9001-63-2, Lysozyme 9001-64-3, Malate dehydrogenase 9001-66-5, Monoamine oxidase 9001-69-8, Ornithine trans-carbamoylase 9001-75-6, Pepsin 9001-78-9, Alkaline phosphatase 9001-80-3, Phosphofructokinase 9001-81-4, Phosphoglucomutase 9001-90-5, Plasmin 9001-99-4 9002-03-3, Dihydrofolate reductase 9002-04-4, Thrombin 9002-06-6, Thymidine kinase 9002-07-7, Trypsin 9002-08-8, Trypsinogen 9002-10-2, Catechol oxidase 9002-12-4, Urate oxidase 9002-13-5, Urease 9002-17-9, Xanthine oxidase 9003-98-9, Deoxyribonuclease 9003-99-0, Myeloperoxidase 9004-02-8, Lipoprotein lipase 9004-06-2, Elastase 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethyl cellulose 9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9005-38-3, Algin 9005-49-6, Heparin, biological studies 9012-25-3, Catechol-O-methyl transferase 9012-42-4, Adenylate cyclase 9012-49-1, Aspartate transcarbamoylase 9012-76-4, Chitosan 9012-78-6, Choline acetyltransferase 9012-90-2, DNA polymerase 9013-02-9, Adenylate kinase 9013-04-1, Nitrogenase 9013-55-2, Blood-coagulation factor XI 9013-56-3, Factor XIII 9013-66-5, Glutathione peroxidase 9013-93-8, Phospholipase 9014-19-1, Pyruvate carboxylase 9014-20-4, Pyruvate dehydrogenase 9014-42-0, Thrombopoietin 9014-52-2, Tryptophan synthase 9015-82-1, Angiotensin-converting enzyme 9015-94-5, Renin, biological studies 9016-11-9, Galactose-1-phosphate uridylyltransferase 9016-12-0, Hypoxanthine-guanine phosphoribosyltransferase 9023-56-7, CTP synthase 9023-58-9, Argininosuccinate synthetase 9023-93-2, Acetyl-CoA carboxylase 9024-60-6, Ornithine decarboxylase 9024-78-6, Kynureninase 9024-90-2, Nitrilase 9026-81-7, Nuclease 9026-93-1, Adenosine deaminase 9027-03-6, Coenzyme Q-cytochrome c reductase 9027-23-0, RubisCO 9027-41-2, Hydrolase 9028-13-1, Homoserine dehydrogenase 9028-14-2, Glycerol dehydrogenase 9028-15-3, Propanediol phosphate dehydrogenase 9028-16-4, D-Xylulose reductase 9028-17-5, L-Xylulose reductase 9028-35-7, 3-Hydroxy-3-methylglutaryl CoA reductase 9028-49-3, Diacetyl reductase 9028-69-7, Methylenetetrahydrofolate reductase 9028-78-8, L-Gulonolactone oxidase 9028-86-8, Acetaldehyde dehydrogenase 9029-22-5, Sarcosine oxidase 9029-38-3, Sulfite oxidase 9029-53-2, Cytochrome c peroxidase 9029-72-5, 4-Hydroxyphenylpyruvate dioxygenase 9029-73-6, Phenylalanine hydroxylase 9030-23-3, Platelet derived endothelial cell growth factor 9030-35-7, Thiaminase 9031-11-2, Lactase 9031-28-1, Thyroid peroxidase 9031-37-2, Ceruloplasmin 9031-44-1, Kinase (phosphorylating) 9031-72-5, Alcohol dehydrogenase 9034-39-3, Growth Hormone Releasing Factor 9035-82-9, Dehydrogenase 9037-14-3, Aminolevulinic acid synthase 9037-42-7 9039-48-9, Aromatase 9042-64-2, Aromatic-L-amino acid decarboxylase 9046-27-9 9046-38-2,

Polygalacturonic acid 9054-63-1, Alanine aminopeptidase 9054-75-5, Guanylate cyclase 9054-89-1, Superoxide dismutase 9055-11-2 9057-02-7, Pullulan 9061-61-4, Nerve growth factor 9067-75-8, Blood-coagulation factor XIIIa 9068-38-6, Reverse transcriptase 9068-57-9, Acrosin 9073-60-3 9074-10-6, Biliverdin reductase 9074-14-0, Thioredoxin reductase 9075-08-5 9075-42-7, Cytochrome P450 oxidase 9075-65-4, Glycerol-3-phosphate dehydrogenase 9076-80-6 9079-67-8 9081-34-9, 5-α Reductase 11096-26-7, Erythropoietin 11100-70-2, Vanadium steel, biological studies 12033-89-5, Silicon nitride, biological studies 12597-68-1, Stainless steel, biological studies 12683-48-6 14378-12-2, Steatite 25249-06-3, Polygalacturonic acid 37205-63-3, ATP synthase 37228-74-3 37250-13-8 37259-58-8 37270-94-3, Platelet factor 4 37288-39-4 37289-19-3, GTP cyclohydrolase I 37318-49-3, Protein disulfide isomerase 42200-33-9, Nadolol 49557-75-7 50812-37-8, Glutathione S-transferase 52013-44-2 53986-32-6, Protoporphyrinogen oxidase 57285-09-3, Inhibin 60202-16-6, Protein C 61869-41-8, Renilla luciferase 61912-98-9, Insulin-like growth factor 61969-99-1, Cypridina luciferase 61970-00-1, Firefly luciferase 62031-54-3, Fibroblast growth factor 62213-29-0 62229-50-9, Epidermal growth factor 62571-86-2, Captopril 62683-29-8, Colony-stimulating factor 63774-49-2 64885-96-7, Primase 72103-04-9, Deiodinase 73200-91-6, DMSO reductase 74870-74-9, Uridine monophosphate synthase 75847-73-3, Enalapril 80449-02-1 80498-15-3, Laccase 81669-70-7 86480-67-3, Ubiquitin carboxyterminal hydrolase 106956-32-5, Oncostatin M 114051-83-1, Dihydrobenzophenanthridine oxidase 117147-70-3, Amphiregulin 125978-95-2 127464-60-2, Vascular endothelial growth factor 139639-23-9, Tissue plasminogen activator 141907-41-7 142008-29-5, CAMP-dependent protein kinase 148348-15-6, Fibroblast growth factor 7 154531-34-7, HB-EGF 154947-66-7, LL-37 163150-12-7, Betacellulin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and storage of stable, biol. active materials)

L11 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:706021 CAPLUS
DN 147:125831
TI Transdermal delivery of pharmaceutical agent comprising genetic molecule
IN Russell-Jones, Gregory J.; Luke, Michael R.; Himes, Stewart R.
PA Apollo Life Sciences Limited, Australia
SO PCT Int. Appl., 121pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007070983	A1	20070628	WO 2006-AU1999	20061222
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006326870	A1	20070628	AU 2006-326870	20061222
	US 20070243132	A1	20071018	US 2006-645122	20061222

EP 1978997 A1 20081015 EP 2006-840407 20061222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
PRAI US 2005-753454P P 20051222
AU 2006-905107 A 20060915
WO 2006-AU1999 W 20061222
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The present invention generally relates to a vehicle useful for delivering a pharmaceutically active compound including a genetic mol. or composition More particularly, the present invention provides microemulsions for transdermal delivery of pharmaceutically active agents to a subject. Thus, stable microemulsion was formed by mixing 16 g of oil (Crodamol GTCC and Capmul MCM, at 3:1 ratio) with 4 g of surfactant and cosurfactant (Brij 72 and Brij 97, at the ratio of 3:1) and stirring until clear. Water phase containing one or more water-soluble pharmaceutical agents was then added (0.5 mL). Microemulsion formation occurred following gentle shaking of the oil and water phases.
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
IT 50-33-9, Phenylbutazone, biological studies 50-78-2, Aspirin 51-21-8, 5-Fluorouracil 51-45-6, Histamine, biological studies 52-67-5, Penicillamine 53-86-1, Indomethacin 54-62-6, Aminopterin 55-86-7, Nitrogen mustard 56-87-1D, Lysine, copper complex 57-27-2, Morphine, biological studies 57-42-1, Pethidine 57-88-5, Cholesterol, biological studies 57-92-1, Streptomycin 58-00-4, Apomorphine 58-05-9, Folinic acid 58-08-2, Caffeine, biological studies 58-74-2, Papaverine 58-85-5, Biotin 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-30-3D, Folic acid, complexes 59-43-8, Thiamine, biological studies 59-67-6, Niacin, biological studies 60-00-4, EDTA, biological studies 60-18-4D, Tyrosine, copper complex 61-68-7, Mefenamic acid 64-17-5, Ethanol, biological studies 65-22-5, Pyridoxal hydrochloride 65-23-6, Pyridoxine 66-71-7D, 1,10-Phenanthroline, copper complex 67-43-6, Diethylenetriaminepentaacetic acid 67-56-1, Methanol, biological studies 67-66-3, Chloroform, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 68-12-2, DMF, biological studies 68-19-9D, Vitamin B12, carboxylic acid derivs. 68-19-9D, Vitamin B12, indium-111-DTPA complex 69-72-7, Salicylic acid, biological studies 70-51-9, Deferoxamine 71-43-2, Benzene, biological studies 72-14-0D, Sulfathiazole, copper complex 75-09-2, Methylene chloride, biological studies 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-99-3, Methadone 79-17-4, Aminoguanidine 81-81-2, Warfarin 83-88-5, Riboflavin, biological studies 97-77-8, N,N,N',N'-Tetraethylthiuram disulfide 98-92-0, Niacinamide 99-66-1D, Valproic acid, copper complex 102-07-8, Carbanilide 108-89-4, 4-Picoline 108-99-6, 3-Picoline 109-89-7, Diethylamine, biological studies 109-99-9, Tetrahydrofuran, biological studies 110-15-6, Succinic acid, biological studies 110-27-0, Isopropyl myristate 110-54-3, Hexane, biological studies 110-86-1, Pyridine, biological studies 111-62-6, Ethyl oleate 112-24-3 123-99-9, Azelaic acid, biological studies 124-18-5, n-Decane 125-28-0, Dihydrocodeine 127-19-5, N,N-Dimethylacetamide 128-62-1, Noscapine 129-20-4, Oxyphenobutazone 130-26-7, Clioquinol 139-13-9, Nitrilotriacetic acid 142-73-4, Iminodiacetic acid 142-91-6, Isopropyl palmitate 144-62-7, Oxalic acid, biological studies 147-84-2, biological studies 254-04-6, 2H-1-Benzopyran 288-32-4D, Imidazole, copper complex 300-85-6, β-Hydroxybutyric acid 305-03-3, Chlorambucil 357-56-2, Dextromoramide 359-83-1, Pentazocine 366-18-7D, 2,2'-Bipyridine, copper complex 404-86-4, Capsaicin 427-00-9, Desomorphine 437-38-7, Fentanyl 443-48-1D, Metronidazole, copper complex 458-37-7, Curcumin 466-90-0, Dihydrocodeinone enol acetate 466-99-9, Hydromorphone

469-62-5, Dextropropoxyphene 479-12-9, Coumestan 484-11-7D, 2, 9-Dimethyl-1,10-phenanthroline, copper complex 509-60-4, Dihydromorphine 521-96-0 529-23-7D, 2-Aminobenzaldehyde, copper complex 530-78-9, Flufenamic acid 552-94-3, Salsalate 556-50-3D, Glycylglycine, copper complex 561-27-3, Diamorphine 574-12-9, Isoflavone 615-15-6, 2-Methylbenzimidazole 616-47-7, 1-Methylimidazole 644-62-2 693-98-1, 2-Methylimidazole 737-86-0, Pyridoxal isonicotinoylhydrazone 796-42-9 822-89-9 867-44-7 869-52-3, Triethylenetetraminehexaacetic acid 872-50-4, n-Methylpyrrolidone, biological studies 1121-23-9 1215-55-0, 2-Pyridylcarboxaldehyde benzoylhydrazone 1310-73-2, Sodium hydroxide, biological studies 1338-41-6, Crill 3 1338-43-8, Crill 4 1403-66-3, Gentamycin 1404-04-2, Neomycin 1406-05-9, Penicillin 1406-18-4, Vitamin E 1691-79-8 1984-15-2D, technetium complex 2149-70-4 2418-14-6, Dimercaptosuccinic acid 2480-28-6 2942-42-9, 7-Nitroindazole 3232-37-9, Salicylaldehyde benzoylhydrazone 4076-02-2, DMPS 4394-00-7, Niflumic acid 5003-48-5, Benorylate 5104-49-4, Flurbiprofen 5178-05-2 5445-51-2, 1,1-Cyclobutanedicarboxylic acid 5460-34-4 5542-28-9D, Diadenosine tetraphosphate, technetium-99 complex 5691-79-2, 7-Nor-7-bromoriboflavin 5868-05-3, Niceritrol 6220-25-3 6956-53-2 7146-48-7, 7-Nor-7-chlororiboflavin 7440-06-4, Platinum, biological studies 7440-25-7, Tantalum, biological studies 7440-29-1, Thorium-232, biological studies 7440-50-8D, Copper, complexes 7440-58-6, Hafnium, biological studies 7440-66-6, Zinc, biological studies 7782-49-2, Selenium, biological studies 7784-30-7, Aluminum phosphate 8059-24-3, Vitamin B6 9001-73-4, Papain 9002-60-2, Adrenocorticotropin, biological studies 9002-61-3, Chorionic gonadotropin 9002-62-4, Prolactin, biological studies 9002-64-6, Parathyroid hormone 9002-67-9, Luteinizing hormone 9002-71-5, Thyroid stimulating hormone 9002-72-6, Somatotropin 9004-10-8, Insulin, biological studies 9004-98-2, Brij 97 9005-00-9, Brij 72 9005-49-6, Heparin, biological studies 9005-65-6, Crillet 4 9005-66-7, Crillet 2 9005-67-8, Crillet 3 9005-80-5, Inulin 9007-12-9, Calcitonin 9007-92-5, Glucagon, biological studies 9014-42-0, Thrombopoietin 9015-68-3, Asparaginase 9026-93-1, Adenosine deaminase 9034-39-3, Growth Hormone Releasing Hormone 9035-58-9, Blood-coagulation factor III 9038-70-4, Somatomedin 9049-98-3, Arlacel A 9061-61-4, NGF 9068-52-4, Phosphodiesterase type 5 10045-97-3, Cesium-137, biological studies 10098-91-6, Yttrium-90, biological studies 10098-97-2, Strontium-90, biological studies 10103-46-5, Calcium phosphate 10198-40-0, Cobalt-60, biological studies 11000-17-2, Vasopressin 11103-57-4, Vitamin A 12775-34-7, 99m-Tc-DTPA 13010-20-3, Nitrosurea 13115-03-2, Vitamin B12-57Co 13291-61-7, CDTA 13408-78-1, Cobalamin 13408-78-1D, Cobalamin, alkylated 13408-78-1D, Cobalamin, derivs. 13422-51-0, Hydroxocobalamin 13422-52-1, Aquocobalamin 13422-53-2, Vitamin B12-60Co 13422-55-4, Methylcobalamin 13822-09-8, Benzyl peroxide 13870-90-1, Adenosylcobalamin 13966-02-4, Beryllium-7, biological studies 13966-05-7, Calcium-45, biological studies 13966-06-8, Tin-113, biological studies 13966-31-9, Manganese-54, biological studies 13966-32-0, Sodium-22, biological studies 13967-48-1, Ruthenium-106, biological studies 13967-63-0, Scandium-46, biological studies 13967-71-0, Zirconium-95, biological studies 13967-73-2, Strontium-85, biological studies 13967-74-3, Cerium-141, biological studies 13967-76-5, Niobium-95, biological studies 13968-51-9, Thallium-204, biological studies 13968-53-1, Ruthenium-103, biological studies 13981-14-1, Protactinium-233, biological studies 13981-37-8, Nickel-63, biological studies 13981-38-9, Cobalt-58, biological studies 13981-50-5, Cobalt-57, biological studies 13981-51-6, Mercury-197, biological studies 13982-30-4, Cerium-139, biological studies 13982-36-0, Yttrium-88, biological studies 13982-38-2, Bismuth-207, biological studies 13982-39-3, Zinc-65, biological studies 13982-63-3, Radium226,

biological studies 13982-78-0, Mercury-203, biological studies
13983-27-2, Krypton-85, biological studies 13994-20-2, Neptunium-237,
biological studies 14093-03-9, Cobalt-56, biological studies
14109-32-1, Cadmium-109, biological studies 14119-15-4, Molybdenum-99,
biological studies 14119-24-5, Osmium-191, biological studies
14158-27-1, Strontium-89, biological studies 14234-24-3, Yttrium-91,
biological studies 14234-28-7, Tellurium-132, biological studies
14234-35-6, Antimony-125, biological studies 14255-04-0, Lead-210,
biological studies 14265-71-5, Selenium-75, biological studies
14269-74-0, Neodymium-147, biological studies 14269-78-4, Ytterbium-169,
biological studies 14274-82-9, Thorium-228, biological studies
14276-65-4, Gadolinium-153, biological studies 14304-78-0, Arsenic-74,
biological studies 14320-93-5, Gold-195, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal delivery of pharmaceutical agent comprising genetic mol.)

IT 14331-97-6, Vanadium-48, biological studies 14344-49-1D, technetium-99
complex 14380-75-7, Promethium-147, biological studies 14390-73-9,
Tellurium-125, biological studies 14391-11-8, Gold-199, biological
studies 14391-94-7, Scandium-44, biological studies 14392-01-9,
Vanadium-49, biological studies 14392-02-0, Chromium-51, biological
studies 14596-12-4, Iron-59, biological studies 14681-59-5, Iron-55,
biological studies 14683-10-4, Antimony-124, biological studies
14683-23-9, Europium-152, biological studies 14694-69-0, Iridium-192,
biological studies 14708-95-3 14762-78-8, Cerium-144, biological
studies 14762-94-8, Atomic fluorine, biological studies 14798-08-4,
Barium-140, biological studies 14932-41-3, Tungsten-185, biological
studies 14932-53-7, Rubidium-86, biological studies 14967-68-1,
Palladium-103, biological studies 14978-39-3, Thiocyanatocobalamin
14981-79-4, Praseodymium-143, biological studies 14998-63-1,
Rhenium-186, biological studies 15017-21-7 15017-32-0,
2-Pyridylcarboxaldehyde isonicotinoylhydrazone 15041-07-3,
Chlorocobalamin 15117-53-0, Sulfur-35, biological studies 15307-86-5,
Diclofenac 15537-71-0, N-Acetyl-D-penicillamine 15671-27-9,
Sulfitocobalamin 15720-36-2, Cobalt-64, biological studies 15749-33-4,
Titanium-44, biological studies 15750-13-7, Hafnium-175, biological
studies 15750-15-9, Indium-111, biological studies 15750-15-9D,
Indium-111, complexes, biological studies 15760-04-0, Silver-111,
biological studies 15766-50-4, Osmium-185, biological studies
15776-19-9, Bismuth-206, biological studies 15840-13-8, Erbium-169,
biological studies 16867-04-2, 3-Hydroxypyridin-2-one 17035-90-4,
L-NMMA 18195-32-9, Vitamin B12-58Co 19342-73-5 20623-13-6,
Nitrocobalamin 20653-75-2, Thallium-170, biological studies
21256-18-8, Oxaprozin 21645-51-2, Aluminum hydroxide, biological studies
22071-15-4, Ketoprofen 22105-10-8 22131-79-9, Alclofenac 22204-53-1,
Naproxen 22494-42-4, Diflunisal 22608-11-3, Demethoxycurcumin
25496-72-4, Glyceryl monooleate 26159-34-2, Sodium naproxen
26171-23-3, Tolmetin 26402-22-2, Glycerol monocaprate 26402-26-6,
Glyceryl monocaprylate 27194-74-7, Propylene glycol monolaurate
27203-92-5, Tramadol 27988-97-2, Tetrazole 28721-76-8 29256-90-4,
Diaminocyclohexane 29679-58-1, Fenoprofen 30346-87-3, Methylimidazole
30652-11-0, 1,2-Dimethyl-3-hydroxypyridin-4-one 31565-12-5, Propylene
glycol monocaprylate 33171-05-0, Bisdemethoxycurcumin 34502-77-7,
Adeninylpropylcobalamin 34552-84-6, Isoxicam 34645-84-6, Fenclofenac
35998-29-9, HBED 36062-04-1, Tetrahydrocurcumin 36322-90-4, Piroxicam
36557-16-1, Sodium curcuminate 37517-28-5, Amikacin 38194-50-2,
Sulindac 40371-66-2 40828-46-4, Suprofen 41340-25-4, Etodolac
41632-95-5, α-(5,6-Dimethylbenzimidazolyl)hydrogenobamide
42924-53-8, Nabumetone 50903-99-6, L-NAME 51037-30-0, Acipimox
51110-01-1, Somatostatin 51481-61-9D, Cimetidine, copper complex
52454-37-2, 10-Deazaminopterin 52485-79-7, Buprenorphine 53188-07-1,
Trolox 53716-49-7, Carprofen 55079-83-9, Acitretin 55565-91-8,

Vitamin B12-56Co 56226-23-4, Adeninylpentylcobalamin 59209-78-8, Adeninylethylcobalamin 59804-37-4, Tenoxicam 60118-07-2, Endorphin 60239-18-1, DOTA 60607-61-6 61512-21-8, Thymosin 62229-50-9, EGF 62683-29-8, CSF 64425-90-7, Choline magnesium trisalicylate 66064-11-7, IL-16 66357-35-5, Ranitidine 66594-14-7, Quil-A 69146-59-4, Mecam 69879-23-8, 6-Hydrazinonicotinamide 69879-23-8D, 6-Hydrazinonicotinamide, technetium complex 71125-38-7, Meloxicam 71195-58-9, Alfentanyl 74103-06-3, Ketorolac 74421-58-2, 1,3,5-Cyclohexanetriamine 76474-56-1, Dihydrocurcumin 80529-93-7D, Gadopentetic acid, albumin-biotin derivs. 80576-83-6, 10-Ethyl-10-deazaaminopterin 83678-67-5, Gadolinium-DOTA 83834-39-3 83869-56-1, Granulocyte-macrophage colony-stimulating factor 83916-01-2, Biphalin 85721-33-1D, Ciprofloxacin, technetium complex 95215-51-3 95215-59-1 95693-76-8, 5,10-Dideazatetrahydrofolic acid 97772-99-1 104625-48-1, Activin A 106096-93-9, BFGF 106956-32-5, Oncostatin M 107514-77-2, Trencam 114011-30-2 114093-40-2 116324-89-1 116324-91-5 116371-34-7D, technetium-99 complex 116489-30-6 117147-70-3, Amphiregulin 126055-13-8 126150-97-8, BAPTA AM 127464-60-2, Vascular endothelial growth factor 127902-98-1, Staphyloferrin A 133587-14-1 138846-62-5, Rhizoferrin 139261-92-0 141760-45-4, Furin 143011-72-7, Granulocyte colony-stimulating factor 143621-35-6, Triapine 144761-33-1 151185-16-9, Fibroblast growth factor 9 151769-16-3, TACE proteinase 156259-68-6, Capmul MCM 156586-89-9, Edrecolomab 158069-81-9 158736-49-3, β-Secretase 158833-85-3 158833-86-4 159356-07-7, TRENHOPO 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 177660-40-1, Tachypyridine 180288-69-1, Trastuzumab 181695-72-7, Valdecoxib 184677-53-0 185915-21-3, Fibroblast growth factor 11 186037-48-9, 99Tc-RP 128 192391-48-3, Bexxar 198470-84-7, Parecoxib 201530-41-8, ICL 670A 205923-56-4, Cetuximab 205923-57-5, Epratuzumab 206264-05-3, RP 517 216503-57-0, Alemtuzumab 216503-58-1, Mitumomab 216974-75-3, Avastin 220578-59-6, Mylotarg 262421-84-1, 2-Pyridylcarboxaldehyde m-bromobenzoylhydrazone 331731-18-1, Humira 339152-71-5, MDX 210 378784-24-8, Silver-110m, biological studies 378784-45-3, Technetium-99m, biological studies 378784-45-3D, Technetium-99m, complexes, biological studies 449736-66-7 449736-67-8 479251-92-8 479578-27-3D, EC 20, technetium-99 complex 581804-97-9 581804-98-0 646032-04-4, Pemtumomab 646032-07-7, Zamyl 646069-62-7 677027-98-4, 99Mtc-trodat-M 702701-36-8, biological studies 753434-12-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal delivery of pharmaceutical agent comprising genetic mol.)

L11 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:201565 CAPLUS
DN 146:268211
TI Gene expression profiling in isolated hepatocytes in the analysis of hepatotoxicity
IN Mendrick, Donna L.; Elashoff, Michael; Orr, Michael S.; Porter, Mark W.
PA Gene Logic, Inc., USA
SO PCT Int. Appl., 140pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007022419	A2	20070222	WO 2006-US32336	20060817
WO 2007022419	A3	20090416		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,

KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2005-708754P P 20050817

AB The present invention includes methods of predicting hepatotoxicity of test agents and methods of generating hepatotoxicity prediction models using algorithms for analyzing quant. gene expression information. The invention also includes microarrays, computer systems comprising the toxicity prediction models, as well as methods of using the computer systems by remote users for determining the toxicity of test agents.

IT Transport proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (choline transporter, gene for, as marker of hepatotoxicity; gene expression profiling in isolated hepatocytes in anal, of hepatotoxicity)

IT 9000-88-8, D-Amino acid oxidase 9000-96-8, Arginase 9001-48-3, Glutathione reductase 9001-50-7, Glyceraldehyde-3-phosphate dehydrogenase 9001-51-8, Glucokinase 9001-64-3, Malate dehydrogenase 9001-77-8, Acid phosphatase 9001-78-9, Alkaline phosphatase 9001-81-4, Phosphoglucomutase 9002-12-4, Urate oxidase 9002-62-4, Prolactin, biological studies 9004-02-8, Lipoprotein lipase 9007-43-6, Cytochrome c, biological studies 9012-38-8, 3'-Phosphoadenosine 5'-phosphosulfate synthase 9012-39-9, 3'-Phosphoadenosine 5'-phosphosulfate synthase 9012-52-6, Methionine adenosyltransferase 9013-18-7, Acyl-CoA synthetase 9013-66-5, Glutathione peroxidase 9013-75-6, Histidine ammonia lyase 9013-81-4, IMP cyclohydrolase 9014-01-1, Subtilisin 9014-27-1, Serine dehydratase 9014-42-0, Thrombopoietin 9014-51-1, Tryptophan 2,3-dioxygenase 9015-81-0, Hydroxysteroid 17β-dehydrogenase 9016-18-6, Carboxylesterase 9023-93-2, Acetyl-Coenzyme A carboxylase 9024-25-3, Aconitase 9024-60-6, Ornithine decarboxylase 9024-78-6, Kynureninase 9025-54-1, Adenosylhomocysteine hydrolase 9025-62-1, Steroid sulfatase 9025-77-8, Phosphatidic acid phosphatase 9026-04-4, Thiosulfate sulfurtransferase 9026-09-9, Phenol sulfotransferase 9026-23-7, Carbamoyl-phosphate synthetase 9026-33-9, Ethanolamine phosphate cytidylyltransferase 9026-67-9, Choline kinase 9027-13-8, Enoyl coenzyme A hydratase 9027-33-2, Arylamine N-acetyltransferase 9027-44-5, 3-Hydroxy-3-methylglutaryl-Coenzyme A synthase 9027-46-7, Acetyl-coenzyme A acetyltransferase 9028-32-4, Glyoxylate reductase 9028-35-7, 3-Hydroxy-3-methylglutaryl-Coenzyme A reductase 9028-40-4, 3-Hydroxyacyl Coenzyme A dehydrogenase 9028-41-5, Hydroxyacyl-Coenzyme A dehydrogenase 9028-56-2, 3-α-Hydroxysteroid dehydrogenase 9028-67-5, Choline dehydrogenase 9028-86-8, Aldehyde dehydrogenase 9029-12-3, Glutamate dehydrogenase 9029-32-7, Guanosine monophosphate reductase 9029-50-9, 3-Hydroxyanthranilate 3,4-dioxygenase 9029-61-2, Kynurenine 3-monooxygenase 9029-72-5, 4-Hydroxyphenylpyruvic acid dioxygenase 9029-97-4, 3-Ketoacyl-Coenzyme A thiolase 9030-08-4, UDP-glucuronosyltransferase 9030-42-6 9030-74-4, Dihydropyrimidinase 9031-72-5, Alcohol dehydrogenase 9032-03-5, 5-Aminoimidazole-4-carboxamide ribonucleotide formyltransferase 9032-20-6, NAD(P)H dehydrogenase 9032-28-4, Dihydrolipoamide succinyltransferase 9032-68-2, Cathepsin C 9035-39-6, Cytochrome b5 9035-51-2, Cytochrome P450, biological studies 9036-21-9, Cyclic nucleotide phosphodiesterase 9036-37-7, δ-Aminolevulinate dehydratase 9037-14-3, Aminolevulinic acid synthase 9037-42-7, DNA (cytosine-5-)-methyltransferase 9040-75-9, Monoglyceride lipase

9045-77-6, Fatty acid synthase 9046-27-9 9054-84-6, Xanthine dehydrogenase 9055-72-5, Pyridoxine 5'-phosphate oxidase 9059-22-7, Heme oxygenase 9059-25-0 9059-44-3, Hydroxypyruvate reductase 9068-41-1, Carnitine palmitoyltransferase 9068-57-9, Acrosin 9073-70-5, Pyruvate dehydrogenase phosphatase 9074-11-7, Quinoid dihydropteridine reductase 9074-91-3, Hydroxymethylbilane synthase 9080-21-1, 7-Dehydrocholesterol reductase 9082-73-9, Steroid dehydrogenase 37237-44-8, UDP-glucose ceramide glucosyltransferase 37270-64-7, Acyl-CoA thioesterase 37340-89-9, Diaphorase 39369-19-2, Carnitine octanoyltransferase 50812-37-8, Glutathione S-transferase 61116-22-1, Acyl-Coenzyme A oxidase 62213-10-9, Cysteine sulfinic acid decarboxylase 62213-29-0, Dodecenoyl-CoA Δ-isomerase 65979-40-0, Bile acid-Coenzyme A: amino acid N-acyltransferase 67338-98-1 69772-96-9, Palmitoyl Coenzyme A oxidase 75922-84-8, RNA (guanine-7-) methyltransferase 77106-95-7, Carbonyl reductase 78689-77-7, 6-Phosphofructo-2-kinase 80295-41-6, Complement C3 81611-75-8, Fructose-2,6-bisphosphatase 82869-38-3, 2-4-Dienoyl-Coenzyme A reductase 91448-99-6, Cystatin C 95076-93-0, Peptidylprolyl isomerase 97089-82-2, 6-Pyruvoyl-tetrahydropterin synthase 102576-81-8, E.C. 2.4.1.101 103106-89-4, α-Inhibin 106640-75-9, Aldo-keto reductase 111693-80-2, Inositol polyphosphate-4-phosphatase 111839-03-3, N-Acetylglucosamine-1-phosphotransferase 114921-78-7, Sulfotransferase SULT1B1 123644-75-7, Dimethylarginine dimethylaminohydrolase 125752-90-1, GM3 synthase 125978-95-2, Nitric oxide synthase 133876-97-8, Phospholipase A2 137632-07-6, Mitogen activated protein kinase 3 138238-81-0, Endothelin converting enzyme 1 139316-54-4, Epithelin 144114-16-9, Protein tyrosine kinase 2 147014-96-8, Cyclin-dependent kinase 5 148710-29-6, Aflatoxin aldehyde reductase 149316-81-4, 2-Hydroxyphytanoyl-CoA lyase 150316-14-6, Mitogen activated protein kinase kinase 2 151125-25-6, Selenophosphate synthetase 154835-90-2, Adrenomedullin 165245-96-5, Mitogen activated protein kinase 14 170347-45-2, Mitogen-activated protein kinase 7 171715-28-9, FK506 binding protein 12-rapamycin associated protein 1 172522-01-9, AMP-activated protein kinase 177893-51-5, p21-Activated kinase 1 184111-06-6, D-Dopachrome tautomerase 190606-17-8, MAP/microtubule affinity-regulating kinase 1 197664-51-0, Protein kinase STK10 236750-39-3, Receptor-interacting serine-threonine kinase 3 251445-63-3, Growth differentiation factor 15 300857-98-1, Protein tyrosine phosphatase, receptor type, F 301156-53-6, Protein tyrosine phosphatase PTPN11 301167-57-7, Protein tyrosine phosphatase 4a1 327046-95-7, Mitogen activated protein kinase kinase 5 329764-85-4, Cytochrome P 450 1A1 330596-22-0, Cytochrome P 450 1B1 331823-27-9, Cytochrome P 450 2A1 338969-69-0, Cytochrome P 450 2F2 342646-20-2, Protein tyrosine phosphatase, non-receptor type 23 344346-08-3, Cytochrome P 450 4A10 348146-29-2, Cytochrome P450 4A14 376596-92-8, β-Defensin 1 438496-81-2, Sirtuin 440354-11-0, Cytochrome P 450 7A1 440356-15-0, Cytochrome P 450 27A1 440356-60-5, Cytochrome P 450 27B1 440363-68-8, Cytochrome P 450 3A3 440368-52-5, Cytochrome P 450 24 443900-95-6, Glycogen synthase kinase 3β 488850-98-2, Protein kinase Cδ 489395-96-2, Vascular endothelial growth factor A 497830-15-6, Cytochrome P 450 4F2 532438-89-4, Cytochrome P 450 4A22 640755-99-3, Cytochrome P450 2G1
RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene for, as marker of hepatotoxicity; gene expression profiling in isolated hepatocytes in anal, of hepatotoxicity)

L11 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:902703 CAPLUS
DN 143:272498
TI Gene expression profiles in the diagnosis and treatment of Alzheimer's disease

IN Landfield, Philip W.; Porter, Nada M.; Chen, Kuey Chu; Geddes, James; Blalock, Eric
PA University of Kentucky Research Foundation, USA
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005076939	A2	20050825	WO 2005-US3668	20050209
	WO 2005076939	A3	20060706		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20070082350	A1	20070412	US 2006-501226	20060809
PRAI	US 2004-542281P	P	20040209		
	WO 2005-US3668	A	20050209		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Genes showing altered patterns of expression in the brain that are associated with the neurol. changes found in Alzheimer's disease and that can be used in the early diagnosis of the disease, including the incipient form of the disease, are identified. The methods and kits of the invention utilize a set of genes and their encoded proteins that are shown to be correlated with incipient Alzheimer's disease.

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT Gene, animal
RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ESD, expression of, in diagnosis of Alzheimer's disease; gene expression profiles in diagnosis and treatment of Alzheimer's disease)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(F-box and leucine-rich repeat 7, gene for, expression of, in diagnosis of Alzheimer's disease; gene expression profiles in diagnosis and treatment of Alzheimer's disease)

IT 9000-81-1, Acetylcholinesterase 9000-83-3, ATPase 9000-88-8, D-Amino-acid oxidase 9000-92-4, Amylase 9000-95-7, Apyrase 9000-96-8, Arginase 9000-97-9 9001-03-0 9001-12-1, Metalloproteinase 1 9001-15-4, Creatine kinase 9001-18-7, Dihydrolipoamidedehydrogenase 9001-40-5, Glucose-6-phosphate dehydrogenase 9001-41-6, Glucose phosphate isomerase 9001-45-0, β-Glucuronidase 9001-47-2, Glutaminase 9001-50-7, Glyceraldehyde-3-phosphatedehydrogenase 9001-58-5, Isocitrate dehydrogenase 9001-60-9, Lactate dehydrogenase 9001-62-1, Lipase 9001-64-3, Malate dehydrogenase 9001-66-5 9001-67-6, Sialidase 9001-80-3, Phosphofructokinase 9001-81-4, Phosphoglucomutase 9001-83-6, Phosphoglyceratekinase 9001-84-7, Phospholipase A2 9001-86-9, Phospholipase C 9001-88-1, Phosphorylase kinase 9001-99-4 9002-02-2, Succinate dehydrogenase 9002-03-3, Dihydrofolate reductase 9002-62-4, Prolactin, biological studies 9002-76-0, Gastrin 9004-02-8, Lipoprotein lipase 9004-06-2, Matrix

metalloproteinase 12 9007-43-6, Cytochrome c, biological studies 9011-97-6, Cholecystokinin 9012-25-3, Catechol methyltransferase 9012-33-3, Diacetyl-chitobiase 9012-34-4, Acyl phosphatase 9012-38-8, 3'-Phosphoadenosine 5'-phosphosulfate synthase 9012-39-9, 3'-Phosphoadenosine 5'-phosphosulfate synthase 9012-52-6, Methionine adenosyltransferase 9012-93-5, Ferrochelatase 9013-66-5, Glutathione peroxidase 9013-81-4, IMP cyclohydrolase 9014-08-8, Enolase 9014-18-0, Nicotinamidenucleotidetranshydrogenase 9014-19-1, Pyruvate carboxylase 9014-34-0, Fatty acid desaturase 9014-42-0, Thrombopoietin 9014-55-5, Tyrosine aminotransferase 9015-71-8, Corticotropin releasing hormone 9015-83-2, Phosphoribosylpyrophosphatesynthetase 9016-12-0, Hypoxanthinephosphoribosyltransferase 9023-56-7, CTP synthase 9023-64-7, Glutamate-cysteine ligase 9023-70-5, Glutamine synthase 9023-94-3, PropionylCoenzymeA carboxylase 9023-95-4 9024-20-8, Ribulose-5-phosphate 3-epimerase 9024-25-3, Aconitase 9024-58-2, Glutamate decarboxylase 9024-60-6, Ornithine decarboxylase 9024-70-8, Uroporphyrinogendecarboxylase 9024-82-2, Pyrophosphatase 9025-10-9, Adenosine monophosphate deaminase 9025-42-7 9026-05-5, Mercaptopyruvate sulfurtransferase 9026-13-5, Choline phosphotransferase 9026-19-1, Ethanolamine phosphotransferase 9026-48-6, Pantothenate kinase 9026-52-2, Mevalonate kinase 9026-59-9, Guanylate kinase 9027-01-4 9027-03-6, Ubiquinol-cytochrome c reductase 9027-13-8, Enoyl-Coenzyme A hydratase 9027-32-1, Aspartyl-tRNA synthetase 9027-43-4, 3-Oxoacid CoA transferase 9027-46-7, Acetyl-Coenzyme A acetyltransferase 9027-51-4, Acetylglucosamine-phosphate mutase 9027-72-9, Adenosine kinase 9027-73-0, Ecto-5'-nucleotidase 9027-88-7, Short-chain acyl-Coenzyme A dehydrogenase, 9027-89-8, Galactosylceramidase 9027-96-7, Citratesynthase 9028-06-2, Procollagen proline dioxygenase 9028-21-1, Sorbitol dehydrogenase 9028-47-1, Malic enzyme 9028-71-1, Hydroxyacid oxidase 9029-03-2, Dihydroorotate dehydrogenase 9029-12-3, Glutamate dehydrogenase 9029-14-5, Methylenetetrahydrofolatedehydrogenase 9029-32-7, Guanosine monophosphate reductase 9029-73-6, Phenylalanine hydroxylase 9029-74-7, Nicotinamide methyltransferase 9029-75-8, Guanidinoacetate methyltransferase 9029-77-0, Acetylserotonin methyltransferase 9029-78-1, Betaine-homocysteine methyltransferase 9029-83-8, Serine hydroxymethyltransferase 9030-42-6 9030-45-9, Glutamine-fructose-6-phosphate transaminase 9030-74-4, Dihydropyrimidinase 9030-83-5, HMG CoA lyase 9030-90-4, Phosphoserine aminotransferase 9030-96-0, Isoleucine-tRNA synthetase 9031-02-1, Oxoglutarate dehydrogenase 9031-37-2, Ceruloplasmin 9032-29-5, Dihydrolipoamide acetyltransferase 9032-58-0, Geranylgeranyl diphosphate synthase 9032-62-6, Phosphoglyceratemutase 9032-66-0, NAD kinase 9032-71-7, Lanosterol synthase 9032-73-9, Neuropathy target esterase 9032-88-6, Fumarate hydratase 9033-12-9, Glyoxalase I 9033-22-1 9033-53-8, Retinol dehydrogenase 9035-42-1, Cytochrome c1 9036-09-3, Chymotrypsin C 9036-21-9, Phosphodiesterase 4B 9037-35-8, Cerebroside sulfotransferase 9037-65-4, α-L-Fucosidase 9040-59-9, Phosphodiesterase 2A 9040-75-9, Monoglyceridelipase 9046-27-9 9047-22-7, Cathepsin B 9050-76-4, Ribonuclease H2 9054-51-7, Monocytic leukemia zinc finger protein-related factor 9054-65-3, Branched chain aminotransferase 9054-75-5, Guanylate cyclase 9054-89-1, Superoxide dismutase 9055-66-7, Phenylalanine-tRNA synthetase 9055-68-9, Glutamyl-prolyl-tRNA synthetase 9059-25-0, Protocollagen lysyl hydroxylase 9067-83-8, CDP-diacylglycerol synthase 9068-41-1 9068-48-8, Phosphatidylserine synthase 9068-49-9, Phosphatidylglycerophosphate synthase 9068-76-2, Glutamyl-prolyl-tRNA synthetase 9073-56-7 9073-92-1, Arginyl aminopeptidase 9074-02-6, Malic enzyme 9074-87-7, Folate hydrolase 9074-91-3, Hydroxymethylbilane synthase 9075-15-4 9075-59-6, Glutaminyl-tRNA

synthetase 9075-64-3, Prolylcarboxypeptidase 9076-73-7, Fatty acid hydroxylase 9080-21-1, 7-Dehydrocholesterol reductase 12651-28-4, Transcobalamin II 37184-63-7, Inositol phosphatase 37205-54-2, Phosphatidylinositol-4-kinase 37211-76-0, Asparaginyl-tRNA synthetase 37237-43-7, Galactosyltransferase β-1,4-GalT I 37237-44-8, UDP-glucoseceramideglucosyltransferase 37256-36-3, NADH dehydrogenase (ubiquinone) 37256-59-0, Cysteine dioxygenase 37257-21-9, Glutaminyl-peptide cyclotransferase 37270-64-7, Acyl-CoA hydrolase 37278-30-1, Phosphopantetheinyl transferase 37278-34-5, Heparitin sulfotransferase 37278-45-8, 6-Phosphogluconolactonase 37278-88-9, Endo F 37288-24-7, 3'-5'-Exoribonuclease 37289-06-8 37289-16-0, Agmatine ureohydrolase 37289-19-3, GTP cyclohydrolase I 37289-34-2, DUTP pyrophosphatase 37318-49-3, Protein disulfide isomerase 37318-64-2, 5,10-Methenyltetrahydrofolate synthetase 37318-71-1, GMP synthase 37340-55-9, Uroporphyrinogen III synthase 39391-27-0, Sphingosine-1-phosphate lyase 39419-81-3, Holocarboxylase synthetase 39471-28-8, Deoxyguanosinekinase 50812-36-7, Farnesyl diphosphate synthase 50812-37-8, Glutathione transferase 50864-48-7, Sphingosine kinase 1 50936-59-9, Iduronate2-sulfatase 51110-01-1, Somatostatin 51845-53-5, Myosin light chain kinase 51901-16-7, 1-Acylglycerol-3-phosphate acyltransferase 52227-79-9, Prostaglandin E synthase 2 56093-23-3, Secretory loci fucosyltransferase 56941-23-2, MRNA capping enzyme 58319-92-9, ADP-ribosyltransferase 60098-35-3, 2',3'-Cyclic nucleotide 3' phosphodiesterase 60202-07-5, Cholesterol 25-hydroxylase 60382-71-0, Diacylglycerol kinase 60440-29-1, 3'-Repair exonuclease 60529-38-6, Laminac 60571-91-7, Hydroxysteroid dehydrogenase 7 60616-82-2, Cathepsin L 60748-73-4, Cathepsin H 61229-81-0, Methionylaminopeptidase 61642-40-8, 12α-Hydroxysteroid dehydrogenase 62213-29-0, Dodecenoyl-CoA Δ-isomerase 62213-50-7, Serine palmitoyltransferase 62229-50-9, Epidermal growth factor 63551-76-8, Phospholipase Cγ2 63704-96-1, Hemoglobin E2 63774-49-2, Ribonuclease Dicer 65802-86-0, Prostacyclin synthase 65979-36-4, Signal peptidase 66676-66-2, RNA methyltransferase - 67338-98-1 67339-09-7, Thiopurine methyltransferase 67763-96-6, Insulin like growth factor 1 69071-62-1, Hemoglobin L 70712-46-8 71427-00-4, Ribonuclease P 71965-46-3, Cathepsin S 72162-84-6, Prolyl endopeptidase 74505-32-1, Acetylgalactosaminidase 74812-49-0, Ubiquitin-protein ligase 75139-03-6, Holocytochrome c synthetase 75302-32-8 76901-00-3, Platelet-activating factor acetylhydrolase 78689-77-7, 6-Phosphofructo-2-kinase 78990-62-2, Calpain 79079-11-1, Calpastatin 80295-34-7, Complement C1r 80295-35-8, Complement C1s 80295-49-4, Complement C4a 80295-50-7, Complement C4b 80295-53-0, Complement C5 80295-57-4, Complement C7 81181-72-8, γ-Glutamyl carboxylase 81611-75-8, Fructose-2,6-bisphosphatase 81627-83-0, Colony-stimulating factor 1 82249-72-7, EIF2 kinase 82785-45-3, Neuropeptide Y 83268-44-4, Spermidine spermine acetyltransferase 83380-83-0, Esterase D 84067-76-5, Progastricsin 86480-67-3, Deubiquitinating enzyme 89964-14-7, Prothymosin, α
RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene for, expression of, in diagnosis of Alzheimer's disease; gene expression profiles in diagnosis and treatment of Alzheimer's disease)

L11 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:355085 CAPLUS
DN 140:369944
TI Human tissue-specific housekeeping genes identified by expression profiling
IN Aburatani, Hiroyuki; Yamamoto, Shogo
PA NGK Insulators, Ltd., Japan
SO PCT Int. Appl., 372 pp.
CODEN: PIXXD2

DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004035785	A1	20040429	WO 2002-JP10753	20021016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002344094	A1	20040504	AU 2002-344094	20021016
US 20040229233	A1	20041118	US 2003-684422	20031015
PRAI US 2002-418614P	P	20021016		
WO 2002-JP10753	A	20021016		

AB Housekeeping genes commonly expressed in 35 different human tissues, oligonucleotide probes and DNA microarrays containing them, are disclosed.

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, MS4A3 (membrane-spanning 4-domains, subfamily A member 3) (hematopoietic cell-specific)); human tissue-specific housekeeping genes identified by expression profiling)
IT 9026-67-9, Choline kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene CHK; human tissue-specific housekeeping genes identified by expression profiling)
IT 9031-28-1, Thyroid peroxidase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene TPO; human tissue-specific housekeeping genes identified by expression profiling)

L11 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:686480 CAPLUS
DN 139:271433
TI Hepatocyte growth factor exerts a proliferative effect on oval cells through the PI3K/AKT signaling pathway
AU Okano, Jun-Ichi; Shiota, Goshi; Matsumoto, Kazuya; Yasui, Sakiko; Kurimasa, Akihiro; Hisatome, Ichiro; Steinberg, Pablo; Murawaki, Yoshikazu
CS Faculty of Medicine, Department of Multidisciplinary Internal Medicine, Division of Medicine and Clinical Science, Tottori University, Yonago, 683-8504, Japan
SO Biochemical and Biophysical Research Communications (2003), 309(2), 298-304
CODEN: BBRCA9; ISSN: 0006-291X
PB Elsevier Science
DT Journal
LA English
AB Hepatocyte growth factor (HGF) is a potent mitogen for a variety of cells including hepatocytes. While rat oval cells are supposed to be one of hepatic stem cells, biol. effects of HGF on oval cells and their relevant signal transduction pathways remain to be determined The authors sought to investigate them on OC/CDE22 rat oval cells, which are established from the liver of rats fed a choline

-deficient/DL-ethionine-supplemented diet. The oval cells were cultured on fibronectin-coated dishes and stimulated with recombinant HGF, transforming growth factor-α (TGF-α), and thrombopoietin (TPO) under the serum-free medium condition. HGF treatment enhanced [3H]thymidine incorporation into oval cells in a dose-dependent manner. On the contrary, treatment with TGF-α or TPO had no significant effects on [3H]thymidine incorporation into the oval cells. C-Met protein was phosphorylated at the tyrosine residues after the HGF treatment. AKT, extracellular signal-regulated kinase 1/2 (ERK1/2), and p70s6k were simultaneously activated after the HGF stimulation, peaking at 30 min after the treatment. The activation of AKT, p70s6k, and ERK1/2 induced by HGF was abolished by pre-treatment with LY294002, a phosphoinositide 3-OH kinase (PI3K) inhibitor, and U0126, a mitogen-activated protein kinase/ERK kinase (MEK) inhibitor, resp. When the cells were pre-treated with LY294002 prior to the HGF stimulation, the proliferative action of HGF was completely abrogated, implying that the PI3K/AKT signaling pathway is responsible for the biol. effect of HGF. These in vitro data indicate that HGF exerts a proliferative action on hepatic oval cells via activation of the PI3K/AKT signaling pathway.

OSC.G 34 THERE ARE 34 CAPLUS RECORDS THAT CITE THIS RECORD (35 CITINGS)

RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB . . . authors sought to investigate them on OC/CDE22 rat oval cells, which are established from the liver of rats fed a choline -deficient/DL-ethionine-supplemented diet. The oval cells were cultured on fibronectin-coated dishes and stimulated with recombinant HGF, transforming growth factor-α (TGF-α), and thrombopoietin (TPO) under the serum-free medium condition. HGF treatment enhanced [3H]thymidine incorporation into oval cells in a dose-dependent manner. On the contrary, treatment with TGF-α or TPO had no significant effects on [3H]thymidine incorporation into the oval cells. C-Met protein was phosphorylated at the tyrosine residues after. . .

IT Epidermal growth factor receptors
MPL receptor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hepatocyte growth factor and not TGF-α and thrombopoietin exerts proliferative effect on rat liver oval cells through PI3K/AKT signaling pathway)

IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α-; hepatocyte growth factor and not TGF-α and thrombopoietin exerts proliferative effect on rat liver oval cells through PI3K/AKT signaling pathway)

IT 9014-42-0, Thrombopoietin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hepatocyte growth factor and not TGF-α and thrombopoietin exerts proliferative effect on rat liver oval cells through PI3K/AKT signaling pathway)

L11 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2002:777950 CAPLUS

DN 137:273158

TI Methods for diagnosing and treating multiple sclerosis and compositions thereof

IN Trepicchio, William L.; Oestreicher, Judith L.; Leonard, John P.; Dorner, Andrew J.; Hunter, Sharon E.

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 178 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079218	A1	20021010	WO 2002-US9305	20020327
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002305093	A1	20021015	US 2002-305093	20020327
PRAI	US 2001-280572P	P	20010330		
	WO 2002-US9305	W	20020327		

AB The present invention is directed to novel methods for diagnosis and prognosis of Multiple Sclerosis by identifying differentially expressed genes. Moreover, the present invention is also directed to methods that can be used to screen test compds. and therapies for the ability to inhibit multiple sclerosis. Addnl., methods and mol. targets (genes and their products) for therapeutic intervention in multiple sclerosis are described.

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 9000-83-3, ATPase 9001-18-7, Diaphorase 9001-47-2, Glutaminase 9001-85-8, Lysophospholipase 9001-92-7, Endopeptidase 9002-02-2, Succinate dehydrogenase 9013-05-2, Phosphatase 9014-20-4, Pyruvate dehydrogenase 9014-42-0, Thrombopoietin 9015-83-2, Phosphoribosyl pyrophosphate synthetase 9016-11-9, Galactose-1-phosphate uridyltransferase 9023-09-0, Sulfotransferase 9023-70-5, Glutamate-ammonia ligase 9026-22-6, UDP_glucose pyrophosphorylase 9026-30-6, Oligoadenylate synthetase 9026-43-1, Serine threonine kinase 9026-67-9, Choline kinase 9026-93-1, Adenosine deaminase 9027-32-1, Aspartyl-tRNA synthetase 9027-43-4, 3-Oxoacid coenzyme A transferase 9027-56-9, Acetylglucosaminidase 9028-04-0, NADH-coenzyme Q reductase 9028-32-4, Glyoxylate reductase 9028-41-5, Hydroxyacyl-coenzymeA dehydrogenase 9029-77-0, Acetylserotonin methyltransferase 9030-22-2, Uridine phosphorylase 9030-96-0, Isoleucine t-RNA synthetase 9031-72-5, Alcohol dehydrogenase 9033-25-4, Methyl transferase 9036-20-8 9054-49-3, Acetylglucosaminyltransferase 9054-51-7, Histone acetyl transferase 9054-63-1, Alanyl aminopeptidase 9054-89-1, Superoxide dismutase 9068-41-1, Carnitine palmitoyl transferase 9076-57-7, Histone deacetylase 37205-63-3, ATP synthase 37213-50-6, DNA polymerase II 37259-58-8, Serine protease 58319-92-9, ADP ribosyl transferase 60098-35-3, 2', 3'-Cyclic nucleotide 3'-phosphodiesterase 79079-11-1, Calpastatin 79747-53-8, Protein tyrosine phosphatase 80449-01-0, Topoisomerase 85638-41-1, RNA 3'-terminal phosphate cyclase 87588-33-8, Tyrosylprotein sulfotransferase 95076-93-0, Peptidylprolyl isomerase 104645-76-3, Phosphatidyl inositol-4-phosphate 5-kinase 109136-49-4, Ubiquitin specific protease 110071-61-9 117628-82-7, Follistatin 119699-77-3, Inositol polyphosphate 5-phosphatase 125752-90-1, GM3 synthase 140879-24-9, Proteasome 141436-78-4, Protein kinase C 141588-26-3, Leukocyte tyrosine kinase 142008-29-5, CAMP-dependent protein kinase 142243-02-5, Mitogen activated protein kinase 146702-84-3, Mitogen activated protein kinase kinase kinase 161384-16-3, Janus kinase 292850-69-2, Nardilysin 361540-77-4, Protein

phosphatase 2B 372092-80-3, Protein kinase 375798-61-1, Protein phosphatase
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for diagnosing and treating multiple sclerosis and compns. thereof)

L11 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:72748 CAPLUS
DN 136:146104
TI Human stress genes identified using DNA microarrays
IN Chenchik, Alex; Lukashev, Matvey E.
PA Clontech Laboratories, Inc., USA
SO U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 441,920.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20020009730	A1	20020124	US 2001-782909	20010213
PRAI US 1998-222256	B2	19981228		
US 1999-440305	B2	19991117		
US 1999-441920	A2	19991117		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Human stress gene arrays and methods for their use are provided. The subject arrays include a plurality of polynucleotide spots, each of which is made up of a polynucleotide probe composition of unique polynucleotides corresponding to a human stress gene. The average length of the polynucleotide probes is 50-1000 nucleotides. The d. of the spots on the array did not exceed 400/cm2 and the spots had a diameter ranging between 10 and 5000 μm. Furthermore, the number of polynucleotide probe spots on the array ranged between 50 and 2000 nucleotides. The subject arrays find use in hybridization assays, particularly in assays for the identification of differential gene expression of human stress genes. Two hundred thirty-six different human stress genes were identified using this approach.
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
IT 391961-78-7 391961-79-8, Protein (human gene hMSH2) 391961-81-2 391961-83-4 391961-84-5 391961-85-6 391961-86-7 391961-87-8, Protein (human 653-amino acid) 391961-88-9, Protein (human gene hPMS1) 391961-89-0, Protein (human gene hPMS2) 391961-90-3 391961-91-4, MutY (human gene hMYH) 391961-92-5, Beta A4 crystallin (human gene CRYBA4) 391961-94-7, Beta B1-crystallin (human) 391961-95-8, Crystallin beta-B2 (human gene CRYB2B) 391961-96-9, BetaB3 crystallin (human) 391961-97-0, GC kinase (human) 391961-98-1, Protein (human gene CYP2A) 391961-99-2, Protein (human 494-amino acid) 391962-00-8, Protein (human clone 1 489-amino acid) 391962-01-9, Protein (human gene CYP2A) 391962-02-0, Protein (human gene CYP2C) 391962-03-1, Protein (human gene CYP2C) 391962-04-2, Protein (human 370-amino acid) 391962-05-3, Cytochrome P450 (human) 391962-06-4, Cytochrome (human gene CYP2C19) 391962-07-5, Protein (human 551-amino acid) 391962-08-6 391962-09-7 391962-10-0, Human P5 (human) 391962-11-1, Protein (human 724-amino acid) 391962-12-2, Heat-shock protein HSP70B (human) 391962-13-3, Protein (human gene HSPA1L) 391962-14-4 391962-15-5, Heat shock protein (human gene HSPA2) 391962-16-6, Protein (human 493-amino acid) 391962-17-7, Protein (human gene CYP2F1) 391962-18-8 391962-19-9, Protein (human gene CYP1A1) 391962-20-2 391962-21-3 391962-22-4, Carboxylesterase (human) 391962-24-6, Oxygenase, steroid 21-mono- (human) 391962-25-7, Protein (human gene CYP11A) 391962-26-8, Protein (human gene CYP2D) 391962-27-9 391962-28-0 391962-29-1

391962-30-4, Serum paraoxonase (human gene PON) 391962-31-5
391962-32-6, Monoamine oxidase A (human gene MAOA) 391962-35-9,
Monoamine oxidase B (human gene MAOB) 391962-36-0, TB3-1 (human)
391962-37-1 391962-38-2 391962-39-3, UDP-glucuronosyltransfer ase
(human) 391962-40-6 391962-41-7, HsLim15 (human gene HsLIM15)
391962-42-8, Dehydrogenase, acyl coenzyme A (human) 391962-43-9, Protein
(human 290-amino acid) 391962-44-0 391962-48-4, Protein (human
503-amino acid) 391962-49-5, Cytochrome P450 (human gene CYP4A11)
391962-50-8, Hydrolase, bleomycin (human clone 1-1) 391962-51-9,
NADH-cytochrome-b5 reductase (human) 391962-52-0 391962-53-1
391962-54-2, GammaC-crystallin (human gene CRYGC) 391962-55-3, Protein
(human gene CRYG2) 391962-56-4 391962-57-5, Protein (human 511-amino
acid) 391962-58-6, Protein (human gene SOD3) 391962-59-7 391962-60-0
391962-61-1 391962-62-2, Protein (human 270-amino acid) 391962-63-3,
Mu-crystallin (human) 391962-64-4 391962-65-5 391962-66-6, Calnexin
(human) 391962-67-7, Calnexin (human) 391962-68-8 391962-69-9,
Cyclophilin-40 (human) 391962-70-2 391962-71-3, Zeta-crystallin
(human) 391962-72-4 391962-73-5 391962-74-6, Protein (human gene
p23) 391962-75-7, Endonuclease (human) 391962-76-8 391962-77-9,
Protein (human gene PPOL) 391962-78-0, Protein (human gene RAG1)
391962-79-1, Protein (human 108-amino acid) 391962-80-4, Protein (human
gene LIG1) 391962-81-5 391962-82-6, Protein (human gene XPAC)
391962-88-2 391962-89-3 391962-90-6 391962-91-7, Calreticulin (human
RAJI cell gene CALR) 391962-92-8 391962-93-9, αβ-Crystallin
(human) 391962-94-0, Protein (human 95-amino acid) 391962-95-1,
AlphaA-crystallin (human gene CRYA1) 391962-96-2 391962-97-3
391962-98-4 391962-99-5 391963-00-1 391963-01-2, PLC alfa (human)
391963-04-5, P58 (human) 391963-05-6 391963-06-7 391963-07-8, Aryl
sulfotransferase (human) 391963-08-9, Dihydropyrimidine dehydrogenase
(human) 391963-09-0, Helicase II (human gene RAD54L) 391963-10-3
391963-12-5, CSA protein (human clone pCSA5 gene CSA) 391963-13-6
391963-14-7 391963-15-8 391963-16-9, XRCC4 (human) 391963-17-0
391963-18-1 391963-19-2 391963-22-7 391963-23-8, Protein (human
527-amino acid) 391963-24-9, Protein (human 361-amino acid)
391963-28-3 391963-29-4 391963-30-7 391963-31-8 391963-32-9
391963-33-0, Protein (human 304-amino acid) 391963-34-1, Protein (human
377-amino acid) 391963-35-2 391963-36-3 391963-37-4, Protein (human
556-amino acid) 391963-38-5 391963-39-6, Protein (human cell line C32
gene HAP1) 391963-40-9, AP endonuclease 1 (human gene HAP1)
391963-41-0, Heme oxygenase-2 (human) 391963-42-1 391963-43-2,
Colligin (human) 391963-44-3, Collagen binding protein 2 (human)
391963-45-4 391963-46-5 391963-47-6, Protein (human gene RAD54)
391963-48-7 391963-49-8, Protein (human gene XRCC2) 391963-50-1
391963-51-2, Protein (human 515-amino acid) 391963-52-3 391963-53-4
391963-54-5 391963-55-6, Protein (human 1279-amino acid) 391963-56-7
391963-57-8, Protein (human 152-amino acid) 391963-58-9, Immunophilin
(human) 391963-63-6, Protein (human gene IL7R) 391963-64-7, Protein
(human 439-amino acid) 391963-65-8, Interleukin 2 receptor (human)
391963-66-9, Protein (human gene IGF2) 391963-67-0 391963-68-1
391963-69-2, Protein (human 391-amino acid) 391963-70-5, Protein (human
gene MYB) 391963-71-6 391963-72-7 391963-73-8 391963-74-9
391963-75-0 391963-76-1 391963-77-2, Protein (human gene IFNGR1)
391963-78-3 391963-79-4, Adenosine receptor A3 (human) 391963-80-7,
Thrombin receptor (human) 391963-81-8 391963-82-9, GATA-binding
protein (human gene GATA-2) 391963-83-0 391963-84-1 391963-85-2,
Protein (human 448-amino acid) 391963-86-3 391963-87-4 391963-88-5
391963-89-6, DNA-binding protein (human gene SMBP2) 391963-90-9,
Transcription activator (human) 391963-91-0, DNA-binding protein (human)
391963-92-1, CACCC box-binding protein (human) 391963-93-2 391963-94-3
391963-95-4, Prostaglandin E2 receptor (human) 391963-96-5
391963-97-6, AES-1 (human) 391963-98-7 391963-99-8, SRE-binding

protein (human gene CNBP) 391964-00-4, Protein (human 423-amino acid) 391964-01-5, COUP-TF (human) 391964-03-7, DNA-binding protein (human gene APRF) 391964-04-8, HSNF2b (human) 391964-05-9 391964-06-0, DP2 (human clone 3kd11 gene Humdp2) 391964-07-1, Glia maturation factor β (human) 391964-08-2 391964-09-3 391964-10-6, Protein (human gene JUN) 391964-12-8, Protein (human gene CSF1) 391964-13-9 391964-14-0 391964-15-1 391964-16-2, Protein (human gene LAG2) 391964-17-3, Neuroleukin (human) 391964-18-4 391964-19-5, Interleukin 13 (human) 391964-20-8, Thrombopoietin (human) 391964-21-9, Protein (human 640-amino acid) 391964-22-0 391964-23-1 391964-24-2, Protein (human gene BMP1) 391964-25-3, Protein (human gene BMP2) 391964-26-4, Protein (human 92-amino acid) 391964-27-5 391964-28-6, Protein (human gene IGFBP1) 391964-29-7 391964-30-0, Protein (human gene IGFBP1) 391964-31-1, Protein (human gene RNH) 391964-32-2 391964-33-3 391964-34-4, Pleiotrophin (human) 391964-35-5, Interleukin 11 (human gene IL11) 391964-36-6, Stem cell factor (human gene SCF) 391964-37-7 391964-38-8 391964-39-9, Connective tissue growth factor (human) 391964-40-2, Protein (human gene RYK) 391964-41-3 391964-42-4
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; human stress genes identified using DNA microarrays)

IT 391972-71-7, Timeless (human) 391972-72-8 391972-75-1, HSF2BP (human gene HSF2BP) 391972-77-3 391972-80-8 391972-81-9 391972-82-0, MRJ (human gene MRJ) 391972-85-3 391972-86-4, Choline /ethanolamine kinase (human) 391972-88-6 391972-93-3, Rigui (human gene RIGUI) 391972-94-4, HP protein (human gene HP) 391972-95-5 391972-96-6 391972-97-7, Glypican-4 (human gene GPC4) 391972-99-9 391973-00-5 391973-01-6 391973-02-7 391973-03-8 391973-04-9, Adaptor protein X11beta (human) 391973-05-0, Thioredoxin (human) 391973-06-1, Sec61 gamma (human) 391973-08-3 391973-09-4 391973-11-8, Transcriptional repressor E2F-6 (human) 391973-12-9 391973-14-1, Hand1 protein (human) 391973-15-2, SURF-4 (human) 391973-18-5, Signalosome subunit 2 (human gene SGN2) 391973-19-6 391973-20-9, Actin, β- (human) 391973-21-0 391973-22-1 391973-23-2, Basic protein (human 23-kilodalton) 391973-24-3, Ribosomal protein S9 (human) 391973-25-4, Protein (human 685-amino acid) 391973-26-5, Phospholipase A2 (human) 391973-27-6, Protein (human 218-amino acid) 391973-28-7 391973-30-1 391973-31-2 391973-32-3, Protein (human 455-amino acid) 391973-33-4, HGF activator precursor (human) 391973-34-5, Protein (human 271-amino acid) 391973-35-6, Glial growth factor 2 (synthetic human) 391973-36-7, Glial growth factor (synthetic human) 391973-37-8 391973-38-9, Protein (human 91-amino acid) 391973-39-0 391973-40-3, Protein (human 252-amino acid) 391973-41-4, Protein (human gene IL4) 391973-42-5 391973-43-6 391973-44-7, Protein (human 233-amino acid) 391973-45-8 391973-46-9 391973-47-0 391973-48-1 391973-49-2 391973-50-5 391973-51-6 391973-52-7 391973-53-8, Protein (human gene CSF2) 391973-54-9, Integrin alpha subunit (human) 391973-55-0 391973-56-1, Protein (human gene ICAM1) 391973-57-2, Protein (human gene TGFB3) 391973-58-3 391973-59-4 391973-60-7 391973-61-8 391973-63-0, Protein (human gene PAI1) 391973-64-1, GTP-binding protein (human gene RAB5) 391973-65-2, Protein (human 1207-amino acid) 391973-66-3 391973-67-4, Protein (human 135-amino acid) 391973-68-5 391973-69-6 391973-70-9 391973-71-0 391973-72-1 391973-73-2, Amphiphysin (human clone 22-2) 391973-74-3 391973-75-4, Interleukin 2 (human precursor) 391973-76-5, 5-HT1D-type serotonin receptor (human) 391973-77-6 391973-78-7, Tumor suppressor (human brain gene DCC) 391973-79-8, Protein (human 1049-amino acid) 391973-80-1 391973-81-2, Fas ligand (human) 391973-82-3, L-myc protein (human) 391973-83-4, L-myc protein (human gene L-myc)

391973-84-5, Transcription factor RelB (human) 391973-85-6, Protein (human 271-amino acid) 391973-86-7 391973-87-8, Protein (human 239-amino acid) 391973-88-9, Apo-2 ligand (human) 391973-89-0 391973-90-3, Protein (human gene cdc25B) 391973-91-4, Protein (human gene CDC25Hu2) 391973-92-5, P14-CDK inhibitor (human) 391973-93-6 391973-94-7 391973-95-8, Protein (human 187-amino acid) 391973-96-9, Protein (human 313-amino acid) 391973-97-0 391973-98-1 391973-99-2 391974-00-8 391974-01-9 391974-02-0, Protein (human gene TK2) 391974-03-1 391974-04-2, MT-MMP (human) 391974-05-3, MT-MMP (human gene human29) 391974-07-5, Cadherin-11 (human) 391974-08-6, Cadherin-12 (human) 391974-10-0, Cadherin-13 (human) 391974-11-1 391974-12-2, Serine/threonine protein kinase (human) 391974-13-3 391974-14-4 391974-15-5, CD27BP (human cell line HeLa gene Siva) 391974-16-6, Apoptosis inhibitor survivin (human) 391974-17-7 391974-18-8, PLK (human clone PL-5, PL-8, PL-PCR) 391974-19-9, Protein (human gene MET) 391974-20-2, Protein CDC37 (human) 391974-21-3, Protein (human 207-amino acid) 391974-22-4 391974-23-5, Stromelysin-3 precursor (human) 391974-24-6 391974-25-7 391974-27-9 391974-29-1 391974-32-6, Mad protein (human gene hMAD-2) 391974-33-7 391974-34-8, FUSE binding protein 2 (human gene FBP2) 391974-35-9, BTG2 (human gene BTG2) 391974-36-0, Sentrin (human) 391974-37-1, Protein (human 334-amino acid) 391974-38-2 391974-39-3 391974-40-6, Metallothionein (human) 391974-41-7 391974-42-8, MT-1l protein (human clone pBlue-MT-1l) 391974-43-9 391974-44-0, Chk1 (human gene CHK1) 391974-45-1, Protein (human 193-amino acid) 391974-46-2, AP-4 (human gene AP-4) 391974-47-3, Fatty acid synthase (human) 391974-48-4, Protein (human gene c-Ha-ras-1) 391974-49-5, Ornithine decarboxylase (ODC) (human) 391974-50-8, Protein (human clone hhmg2 gene HMG-2) 391974-51-9 391974-52-0, RCL (human gene Rcl) 391974-53-1 391974-54-2, Cyclin K (human gene CPR4) 391974-55-3, Anti-death protein (human gene IEX-1L) 391974-56-4, PAP ous protein (human) 391974-57-5 391974-58-6 391974-59-7, HsGAK (human) 391974-60-0 391974-61-1 391974-62-2 391974-63-3, Neuromedin B (human gene NMB) 391974-64-4, Protein (human 1480-amino acid) 391974-65-5 391974-66-6 391974-67-7, Alpha-1-antitrypsin (aa 268-394) (human) 391974-68-8 391974-69-9 391974-70-2 391974-71-3 391974-72-4 391974-73-5 391974-74-6 391974-75-7, Protein (human 100-amino acid) 391974-76-8, Pre-apolipoprotein CIII (human) 391974-77-9, Protein (human 499-amino acid) 391974-78-0, Cytochrome P450 reductase (human) 391974-79-1, Protein (human 184-amino acid) 391974-80-4, Protein (human gene TIMP) 391974-81-5 391974-82-6 391974-83-7 391974-84-8 391974-85-9 391974-86-0, Protein (human 375-amino acid) 391974-87-1, Esterase, cholesterol (human gene LIPA) 391974-88-2, Protein (human gene ALDH1) 391974-89-3, Precursor peptide (human) 391974-90-6, Protein (human 328-amino acid) 391974-91-7, Protein (human gene FABP2) 391974-92-8, Protein (human gene FABP1) 391974-93-9, Protein (human gene CBG) 391974-94-0 391974-95-1 391974-96-2, Fibrinogen gamma chain (human) 391974-97-3, Protein (human 169-amino acid) 391974-98-4, Protein (human 153-amino acid) 391974-99-5, Endothelin-converting-enzyme 1 (human) 391975-00-1 391975-01-2 391975-02-3 391975-03-4, VLACD (human strain Caucasoid) 391975-04-5, FIC1 (human) 391975-05-6 391975-06-7 391975-07-8 391975-08-9 391975-09-0, Protein (human 504-amino acid) 391975-10-3, Protein (human 503-amino acid) 391975-11-4, Protein (human 502-amino acid) 391975-12-5, Protein (human 503-amino acid) 391975-13-6 391975-14-7, Cholesterol 7-alpha-hydroxylase (human) 391975-15-8, Protein (human gene CYP17) 391975-16-9, Protein (human 424-amino acid) 391975-17-0 391975-18-1, Cyclooxygenase-2 (human gene Cox-2) 391975-19-2, Protein (human gene HMGCR) 391975-20-5, Protein (human gene PRNP) 391975-21-6, Protein (human gene LPL) 391975-22-7, Phospholipase (human) 391975-23-8 391975-24-9, Protein (human gene LBP) 391975-25-0 391975-26-1 391975-28-3, Protein (human gene MMAC1)

391975-29-4 391975-30-7, Protein (human 347-amino acid) 391975-31-8
391975-32-9 391975-33-0, Protein (human 515-amino acid) 391975-34-1
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; human stress genes identified using DNA microarrays)

L11 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:828415 CAPLUS
DN 137:89412
TI Detection of variations in the DNA methylation profile of genes in the determining the risk of disease
IN Berlin, Kurt; Piepenbrock, Christian; Olek, Alexander
PA Epigenomics A.-G., Germany
SO PCT Int. Appl., 636 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 69

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077373	A2	20011018	WO 2001-XA1486	20010406
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, TG				
	DE 10019058	A1	20011220	DE 2000-10019058	20000406
	WO 2001077373	A2	20011018	WO 2001-DE1486	20010406
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001077487	A	20011023	AU 2001-77487	20010406
	EP 1360319	A2	20031112	EP 2001-955278	20010406
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 2014776	A2	20090114	EP 2008-12765	20010406
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
	AT 339520	T	20061015	AT 2002-90203	20020605
	ES 2272636	T3	20070501	ES 2002-90203	20020605
	US 20040067491	A1	20040408	US 2003-240454	20030311
	AU 2003204553	A1	20040108	AU 2003-204553	20030605
	AU 2003204553	B2	20071129		
	JP 2004008217	A	20040115	JP 2003-160375	20030605
	US 20040023279	A1	20040205	US 2003-455212	20030605
	AU 2006203475	A1	20060831	AU 2006-203475	20060811
	AU 2006213968	A1	20061019	AU 2006-213968	20060915
	AU 2006225250	A1	20061026	AU 2006-225250	20061005
PRAI	DE 2000-10019058	A	20000406		
	WO 2001-DE1486	W	20010406		
	DE 2000-10019173	A	20000407		

DE 2000-10032529 A 20000630
DE 2000-10043826 A 20000901
AU 2001-275663 A 20010406
AU 2001-276331 A3 20010406
AU 2001-75663 A 20010406
EP 2001-969303 A3 20010406
WO 2001-EP4016 W 20010406
EP 2002-90203 A 20020605
AU 2006-230475 A 20060811

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to an oligonucleotide kit as probe for the detection of relevant variations in the DNA methylation of a target group of genes. The invention further relates to the use of the same for determining the gene variant with regard to DNA methylation, a medical device, using an oligonucleotide kit, a method for determining the methylation state of an individual and a method for the establishment of a model for establishing the probability of onset of a disease state in an individual. Such diseases may be: undesired pharmaceutical side-effects; cancerous diseases; CNS dysfunctions, injuries or diseases; aggressive symptoms or relational disturbances; clin., psychol. and social consequences of brain injury; psychotic disorders and personality disorders; dementia and/or associated syndromes; cardiovascular disease, dysfunction and damage; dysfunction, damage or disease of the gastrointestinal tract; dysfunction, damage or disease of the respiratory system; injury, inflammation, infection, immunity and/or anastasis; dysfunction, damage or disease of the body as an abnormal development process; dysfunction, damage or disease of the skin, muscle, connective tissue or bones; endocrine and metabolic dysfunction, damage or disease; headaches or sexual dysfunction. This abstract record is one of several records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.

IT Gene, animal
RL: ANT (Analyte); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(PVALB, DNA methylation profiles and disease susceptibility; detection of variations in DNA methylation profile of genes in determining risk of disease)

IT Retinoic acid receptors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(RAR-α, DNA methylation profiles in gene for and disease susceptibility; detection of variations in DNA methylation profile of genes in determining risk of disease)

IT 9000-90-2, α-Amylase 9000-94-6, Antithrombin III 9000-96-8, Arginase 9001-04-1, Pyruvate decarboxylase 9001-05-2, Catalase 9001-10-9, Pepsinogen 9001-12-1, Matrix metalloproteinase 8 9001-16-5, Cytochrome c oxidase 9001-18-7, Dihydrolipoamide dehydrogenase 9001-30-3, Blood-coagulation factor XII 9001-41-6, Phosphoglucose isomerase 9001-42-7, α-Glucosidase 9001-45-0, β-Glucuronidase 9001-47-2, Glutaminase 9001-52-9, Fructose-1,6-diphosphatase 9001-67-6, Neuraminidase 9001-75-6, Pepsin 9001-77-8, Acid phosphatase 9001-80-3, Phosphofructokinase 9001-81-4, Phosphoglucomutase 9001-83-6, Phosphoglycerate kinase 9001-88-1, Phosphorylase kinase 9001-91-6, Plasminogen 9001-97-2, Glycogen branching enzyme 9002-02-2, Succinate dehydrogenase 9002-12-4, Urate oxidase 9002-64-6, Parathyroid hormone 9002-69-1D, Relaxin, isoforms 9002-76-0, Gastrin 9004-02-8, Lipoprotein lipase 9004-06-2, Matrix metalloproteinase 12 9007-43-6, Cytochrome c, biological studies 9012-25-3, Catechol-o-methyltransferase 9012-33-3, Hexosaminidase 9012-47-9, Amylo-1,6-glucosidase 9012-78-6, Choline acetyltransferase 9012-93-5, Ferrochelatase 9013-08-5,

Phosphoenolpyruvate carboxykinase 9013-38-1, Dopamine β-hydroxylase 9013-55-2, Blood-coagulation factor XI 9013-56-3, Factor XIII 9013-75-6, Histidase 9014-08-8, Enolase 9014-19-1, Pyruvate carboxylase 9014-36-2, Succinate thiokinase 9014-42-0, Thrombopoietin 9014-55-5, Tyrosine aminotransferase 9014-56-6, Glycogen synthase 9014-74-8, Enterokinase 9015-81-0, 17β Hydroxysteroid dehydrogenase 9015-82-1, Angiotensin converting enzyme 9015-83-2, Phosphoribosyl pyrophosphate synthetase 9015-94-5, Renin, biological studies 9023-58-9, Arginosuccinate synthetase 9023-64-7, Glutamate cysteine ligase 9023-69-2, Asparagine synthetase 9023-70-5, Glutamine synthase 9023-78-3, Triosephosphate isomerase 9023-90-9, Methylmalonyl CoA mutase 9023-93-2, Acetyl CoA carboxylase 9023-99-8, Cystathionine β synthase 9024-58-2, Glutamate decarboxylase 9024-78-6, Kynureninase 9025-26-7, Cathepsin D 9025-32-5 9025-35-8, α Galactosidase A 9025-42-7, Mannosidase, α 9025-43-8, Mannosidase, β 9025-62-1, Steroid sulfatase 9025-90-5, Hydroxyacyl glutathione hydrolase 9026-22-6, UDP-glucose pyrophosphorylase 9027-21-8, Carnosinase 9027-33-2, N-Acetyltransferase 9027-34-3 9027-43-4, 3-Oxoacid CoA transferase 9027-44-5, HMG-CoA synthase 9027-46-7, Thiolase 9027-56-9, N-Acetylglucosaminidase 9027-65-0, Medium chain Acyl CoA dehydrogenase 9027-88-7, Short chain Acyl CoA dehydrogenase 9027-89-8, Galactocerebrosidase 9027-96-7, Citrate synthase 9028-16-4, Xylitol dehydrogenase 9028-31-3, Aldose reductase 9028-86-8, Aldehyde dehydrogenase 9029-12-3, Glutamate dehydrogenase 9029-38-3, Sulfite oxidase 9029-49-6, Homogentisate 1,2 dioxygenase 9029-61-2, Kynurenine hydroxylase 9029-72-5, 4-Hydroxyphenylpyruvate dioxygenase 9029-73-6 9029-90-7, Carnitine acetyltransferase 9029-97-4, Acetyl CoA acyltransferase 9030-08-4, UDP-glucuronosyltransferase 9030-21-1, Purine nucleoside phosphorylase 9030-42-6, Ornithine δ-aminotransferase 9030-50-6, Ketohexokinase 9030-66-4, Glycerol kinase 9030-83-5, HMG-CoA lyase 9031-02-1, α-Ketoglutarate dehydrogenase 9031-14-5, Lecithin cholesterol acyltransferase 9031-37-2, Ceruloplasmin 9031-72-5, Alcohol dehydrogenase 9031-86-1, Aspartoacylase 9031-96-3, Peptidase A 9032-02-4 9032-15-9, α-Dextrinase 9032-25-1, NADH cytochrome b5 reductase 9032-88-6, Fumarase 9034-40-6, LHRH 9035-34-1, Cytochrome a 9035-58-9, Blood coagulation Factor III 9035-74-9, Glycogen phosphorylase 9035-75-0, Chymotrypsinogen 9036-22-0, Tyrosine hydroxylase 9036-23-1, Uridine monophosphate kinase 9036-37-7, δ-Aminolevulinate dehydratase 9037-21-2, Tryptophan hydroxylase 9037-65-4, Fucosidase, α-L- 9039-53-6, Urokinase 9041-46-7 9042-64-2, DOPA decarboxylase 9044-85-3, 3β Hydroxysteroid dehydrogenase 9047-22-7, Cathepsin B 9050-70-8, Proline dehydrogenase 9054-54-0, Transacylase 9054-65-3, Branched chain aminotransferase 9054-75-5, Guanylyl cyclase 9054-84-6, Xanthine dehydrogenase 9054-89-1, Superoxide dismutase 9054-94-8, Galactosyltransferase, uridine diphosphogalactose-acetylglucosamine 9055-02-1, Prekallikrein 9055-67-8, Poly(ADPribose) synthetase 9056-26-2, Peptidase B 9059-22-7, Heme oxygenase 9061-61-4, Nerve growth factor 9067-69-0, Acetylgalactosaminyltransferase, [blood-group substance] α 9068-68-2, Arylsulfatase A 9068-75-1, Glucagon synthetase 9073-56-7, α-L-Iduronidase 9074-10-6, Biliverdin reductase 9075-24-5, Aspartylglucosaminidase 9079-67-8, NADH dehydrogenase 9080-21-1, 7-Dehydrocholesterol reductase 9082-57-9, Inosine triphosphatase 9082-72-8 11016-39-0, Properdin 11085-36-2, Human placental lactogen 12651-27-3, Transcobalamin I 12651-28-4, Transcobalamin 2 24305-27-9, Thyrotropin releasing hormone 33507-63-0, Substance P 37184-63-7, Inositol monophosphatase 37211-69-1, 2,3-Bisphosphoglycerate mutase 37213-56-2, Factor D 37221-79-7, Vasoactive intestinal polypeptide 37237-43-7, Galactosyltransferase, uridine diphosphogalactose-glycoprotein 37255-32-6, Dihydrodiol

dehydrogenase 37255-38-2, GlutarylCoA dehydrogenase 37255-40-6, Glycine dehydrogenase 37257-19-5, Dihydroxyacetone phosphate acyltransferase 37270-64-7, AcylCoA thioesterase 37274-61-6, Isovaleryl CoA dehydrogenase 37277-69-3, Fucosyltransferase 3 37288-40-7, α-Acetylglucosaminidase 37289-41-1, Sulfamidase 37290-90-7, Methionine synthase 37340-55-9, Uroporphyrinogen III synthase 39346-44-6, Inter-α-trypsin inhibitor 39362-14-6, Prolactin releasing hormone 39379-15-2, Neurotensin 39401-02-0, Coumarin 7-hydroxylase 39419-81-3, Holocarboxylase synthetase 50936-59-9, Iduronate 2 sulfatase 52906-92-0, Motilin 53230-14-1, Preprothrombin 53986-32-6, Protoporphyrinogen oxidase 54004-64-7, Rhodopsin kinase 55354-43-3, Arylsulfatase B 56626-18-7, Fucosyltransferase 56645-49-9, Cathepsin G 59299-00-2, N-Acetylgalactosamine-6-sulfate sulfatase 59536-73-1, Phosphomannomutase 59536-74-2, Long chain Acyl CoA dehydrogenase 60320-99-2, N-Acetylglucosamine-6-sulfatase 60748-73-4, Cathepsin H 61512-21-8, Thymosin 62213-29-0, Enoyl CoA isomerase 62229-50-9, Epidermal growth factor 65802-85-9, Prostaglandin D synthase 66796-54-1, Proopiomelanocortin 67526-96-9, Galactosyltransferase, uridine diphosphogalactose-acetylgalactosamine 3β- 67763-96-6, Insulin like growth factor 1 67763-97-7, Insulin like growth factor 2 68651-94-5 70356-40-0, DNA glycosylase 71822-25-8, 5,10-Methylenetetrahydrofolate reductase (NADPH) 72497-28-0, Cytochrome P 450 8 74812-49-0, Parkin 74870-74-9, UMP synthetase 75922-89-3, Pyrroline-5-carboxylate synthetase 76901-00-3, Platelet activating factor acetylhydrolase 78689-77-7, 6-Phosphofructo-2-kinase 78849-38-4, Leukin 78990-62-2, Calpain 79747-53-8, Protein tyrosine phosphatase 79955-99-0, Matrix metalloproteinase 3 80043-53-4, Gastrin releasing peptide 80295-33-6, Complement C1q 80295-34-7, Complement C1r 80295-35-8, Complement C1s 80295-38-1, Complement C1 inhibitor 80295-40-5, Complement component C2 80295-41-6, Complement component C3 80295-49-4, Complement C4A 80295-50-7, Complement C4B 80295-53-0, Complement C5 80295-56-3, Complement C6 80295-57-4, Complement C7 80295-58-5, Complement C8 80295-59-6, Complement C9 80295-65-4, Complement factor H 80619-02-9, Leukotriene A4 synthase 81604-65-1, Heparin Cofactor II 82249-72-7, Protein kinase HRI 82707-54-8, Neprilysin 82869-38-3, 2,4-Dienoyl CoA reductase 86551-03-3, Electron-transferring flavoprotein dehydrogenase 88402-55-5, Prodynorphin 90597-47-0, Peptidylglycine α-amidating monooxygenase 90698-32-1, Leukotriene C4 synthase 91448-99-6, Cystatin C 92769-12-5, Proliferin 93443-35-7, Preproenkephalin 94716-09-3, Cathepsin K 95567-84-3, Dihydrolipoamide transacylase
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DNA methylation profiles in gene for and disease susceptibility; detection of variations in DNA methylation profile of genes in determining risk of disease)

L11 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:763235 CAPLUS
DN 135:314399
TI Detection of variations in the DNA methylation profile of genes in the determining the risk of disease
IN Berlin, Kurt; Piepenbrock, Christian; Olek, Alexander
PA Epigenomics A.-G., Germany
SO PCT Int. Appl., 636 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 23

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2001077373 A2 20011018 WO 2001-DE1486 20010406
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
DE 10019058 A1 20011220 DE 2000-10019058 20000406
AU 2001073840 A 20011023 AU 2001-73840 20010406
AU 2001077487 A 20011023 AU 2001-77487 20010406
EP 1278892 A1 20030129 EP 2001-940158 20010406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
EP 1360319 A2 20031112 EP 2001-955278 20010406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
EP 2014776 A2 20090114 EP 2008-12765 20010406
EP 2014776 A3 20090401
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR
AT 339520 T 20061015 AT 2002-90203 20020605
ES 2272636 T3 20070501 ES 2002-90203 20020605
US 20040067491 A1 20040408 US 2003-240454 20030311
AU 2003204553 A1 20040108 AU 2003-204553 20030605
AU 2003204553 B2 20071129
JP 2004008217 A 20040115 JP 2003-160375 20030605
US 20040023279 A1 20040205 US 2003-455212 20030605
US 20070026393 A1 20070201 US 2003-240970 20030711
AU 2006203475 A1 20060831 AU 2006-203475 20060811
AU 2006213968 A1 20061019 AU 2006-213968 20060915
AU 2006225250 A1 20061026 AU 2006-225250 20061005
PRAI DE 2000-10019058 A 20000406
DE 2000-10019173 A 20000407
DE 2000-10032529 A 20000630
DE 2000-10043826 A 20000901
AU 2001-275663 A 20010406
AU 2001-276331 A3 20010406
AU 2001-75663 A 20010406
EP 2001-969303 A3 20010406
WO 2001-DE1486 W 20010406
WO 2001-EP4016 W 20010406
EP 2002-90203 A 20020605
AU 2006-230475 A 20060811

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to an oligonucleotide kit as probe for the detection of relevant variations in the DNA methylation of a target group of genes. The invention further relates to the use of the same for determining the gene variant with regard to DNA methylation, a medical device, using an oligonucleotide kit, a method for determining the methylation state of an individual and a method for the establishment of a model for establishing the probability of onset of a disease state in an individual. Such diseases may be: undesired pharmaceutical side-effects; cancerous diseases; CNS dysfunctions, injuries or diseases; aggressive symptoms or relational disturbances; clin., psychol. and social consequences of brain injury; psychotic disorders and personality disorders; dementia and/or associated syndromes; cardiovascular disease, dysfunction and damage; dysfunction, damage or disease of the gastrointestinal tract; dysfunction, damage or disease of the respiratory system; injury, inflammation,

infection, immunity and/or anastasis; dysfunction, damage or disease of the body as an abnormal development process; dysfunction, damage or disease of the skin, muscle, connective tissue or bones; endocrine and metabolic dysfunction, damage or disease; headaches or sexual dysfunction. This abstract record is one of several records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.

IT 50-56-6, Oxytocin, biological studies 70-18-8, Glutathione, biological studies 113-79-1, Arginine vasopressin 1393-25-5, Secretin 9000-83-3, ATPase 9000-90-2 9001-01-8, Kallikrein 9001-03-0, Carbonic anhydrase 9001-05-2, Catalase 9001-08-5, Butyrylcholinesterase 9001-18-7, Dihydrolipoamide dehydrogenase 9001-25-6, Blood-coagulation factor VII 9001-28-9, Factor IX 9001-29-0, Factor X 9001-42-7, Maltase 9001-48-3, Glutathione reductase 9001-50-7, Glyceraldehyde-3-phosphate dehydrogenase 9001-62-1 9001-66-5, Monoamine oxidase 9001-69-8, Ornithine transcarbamoylase 9001-84-7, Phospholipase A2 9001-86-9, Phospholipase C 9002-03-3, Dihydrofolate reductase 9002-62-4, Prolactin, biological studies 9002-64-6, Parathyroid hormone 9002-68-0, Follicle stimulating hormone 9002-71-5, Thyrotropin 9004-02-8, Clearing factor lipase 9004-10-8, Insulin, biological studies 9011-97-6, Cholecystokinin 9012-25-3, Catechol-o-methyltransferase 9012-39-9, ATP sulfurylase 9012-42-4, Adenylate cyclase 9012-49-1, Aspartate transcarbamoylase 9012-52-6, Methionine adenosyltransferase 9012-78-6, Choline acetyltransferase 9012-90-2, DNA polymerase 9013-02-9, Adenylate kinase 9013-66-5, Glutathione peroxidase 9014-24-8, RNA polymerase 9014-42-0, Thrombopoietin 9015-82-1, Angiotensin converting enzyme 9015-83-2, Ribosephosphate pyrophosphokinase 9015-85-4, DNA Ligase 9016-11-9, Galactose 1-phosphate uridyl-transferase 9016-12-0 9016-17-5 9023-26-1, CoA transferase 9023-56-7, Cytidine-5'-triphosphate synthetase 9023-62-5, Glutathione synthetase 9023-88-5, Phosphomannose isomerase 9024-58-2, Glutamate decarboxylase 9024-93-5, Dihydroorotase 9024-99-1, Malonyl CoA decarboxylase 9025-06-3, Cytidine deaminase 9025-10-9, Adenosine monophosphate deaminase 9025-54-1, S-Adenosyl homocysteine hydrolase 9026-23-7, Carbamoylphosphate synthetase 9026-52-2, Mevalonate kinase 9026-59-9, Guanylate kinase 9026-89-5, Dihydrouracil dehydrogenase 9026-93-1, Adenosine deaminase 9027-21-8, Carnosinase 9027-33-2, N-Acetyltransferase 9027-44-5, HMG-CoA synthase 9027-46-7, Acetoacetyl-CoA thiolase 9027-56-9, N-Acetylglucosaminidase 9027-67-2, Terminal deoxynucleotidyltransferase 9027-80-9, Adenine phosphoribosyltransferase 9027-81-0, Adenylosuccinate lyase 9027-88-7, Short chain Acyl CoA dehydrogenase 9028-35-7, HMG-CoA reductase 9028-93-7, Inosine monophosphate dehydrogenase 9028-95-9, Succinic semialdehyde dehydrogenase 9029-75-8 9029-83-8, Serine hydroxymethyltransferase 9029-97-4, Acetyl CoA acyltransferase 9030-21-1, Purine nucleoside phosphorylase 9030-83-5, HMGCOA lyase 9030-87-9 9031-61-2, Thymidylate synthase 9031-82-7, PRPP amidotransferase 9032-02-4 9032-25-1, NADH-cytochrome b5 reductase 9032-29-5 9032-64-8, Nucleotide pyrophosphatase 9032-76-2, Dehydroepiandrosterone sulfotransferase 9033-06-1, Glucosidase 9034-39-3, Somatoliberin 9034-40-6, Gonadotropin releasing hormone 9036-20-8, S-Adenosylmethionine decarboxylase 9037-42-7, DNA methyltransferase 9037-67-6, GABA transaminase 9037-68-7, Phenylethanolamine N-methyltransferase 9039-45-6, Deoxycytidine kinase 9040-59-9, Cyclic nucleotide phosphodiesterase 9041-92-3, α1-Antitrypsin 9046-27-9, γ-Glutamyltransferase 9047-64-7, Ribonucleoside diphosphate reductase 9054-75-5, Guanylyl cyclase 9074-10-6, Biliverdin reductase 9074-91-3, Porphobilinogen deaminase 9076-84-0, Coproporphyrinogen oxidase 9081-34-9, Steroid 5α reductase 9082-57-9, Inosine triphosphatase 9082-72-8, Branched chain

α-keto acid dehydrogenase 11002-13-4, Angiotensinogen (protein renin substrate) 11096-26-7, Erythropoietin 37184-63-7, Inositol monophosphatase 37255-32-6, Dihydrodiol dehydrogenase 37256-36-3, NADH dehydrogenase(ubiquinone) 37256-73-8, Flavin-containing monooxygenase 1 37257-08-2, Aminomethyltransferase 37257-17-3, Malonyltransferase 37277-84-2, Cobalamin adenosyltransferase 37288-39-4, Sucrase 37288-66-7, Aminopeptidase P 37289-19-3, GTP cyclohydrolase 37289-34-2, Deoxyuridine triphosphatase 37290-90-7, Methionine synthase 50812-37-8, Glutathione S-transferase 51110-01-1, Somatostatin 53096-17-6, Bleomycin hydrolase 57576-52-0, Thromboxane A2 58319-92-9, ADP ribosyltransferase 59299-00-2, N-Acetylgalactosamine-6-sulfate sulfatase 60267-61-0, Ubiquitin 60320-99-2, N-Acetylglucosamine-6-sulfatase 60529-76-2, Thymopoietin 60832-04-4, Thromboxane A2 synthase 61811-29-8, Apurinic endonuclease 61969-98-0, Bilirubin UDP glucuronosyltransferase 65802-86-0, Prostacyclin synthase 65979-40-0, Bile acid coenzyme A: amino acid N-acyltransferase 66796-54-1, Proopiomelanocortin 67339-09-7, Thiopurine-S-methyltransferase 70356-40-0, DNA glycosylase 74812-49-0, Ubiquitin protein ligase 77271-19-3, Methylguanine methyltransferase 80619-02-9, Arachidonate 5-lipoxygenase 81181-72-8, γ-Glutamyl carboxylase 81627-83-0, Colony stimulating factor 1 82391-43-3 82785-45-3, Neuropeptide Y 83869-56-1, Colony stimulating factor 2 85637-73-6, Atrialnatriuretic peptide 86480-67-3, Ubiquitin thiol esterase 86933-74-6, Neurokinin A 87683-70-3, Pterin-4α-carbinolamine dehydratase 90119-07-6, Leukotriene A4 hydrolase 90698-26-3, Ribosomal protein S6 kinase 92941-56-5, Serotonin-N-acetyltransferase 93792-73-5, Colony stimulating factor 3 95978-15-7 99676-46-7, Neuroendocrine convertase 1 102577-23-1, Neurokinin B 103370-86-1, Parathyroid hormone-related peptide 105913-04-0 106096-92-8, FGF 1 109319-16-6, Factor VIII 109675-94-7, Placental Growth hormone 117698-12-1, Paraoxonase 137061-48-4, Pituitary adenylate cyclase activating peptide 138757-15-0, α2-Antiplasmin 139639-23-9, Tissue plasminogen activator 142008-29-5, Cyclic AMP-dependent protein kinase 142243-02-5, Mitogen-activated protein kinase 142805-56-9, Topoisomerase II 143180-75-0 144940-98-7, Guanylin 146702-84-3, MAP kinase kinase kinase 148125-60-4, Protease-nexin 2 151821-61-3, Ubiquitin B 151821-62-4, Ubiquitin C 169494-85-3, Leptin 194739-73-6, MAP kinase kinase 6 205944-50-9, Osteoprotegerin 207004-87-3, Methionine synthase reductase 329900-75-6, Cyclooxygenase 2 329967-85-3, Cyclooxygenase 1 361540-77-4, Calcineurin

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(detection of methylation in gene for; detection of variations in DNA methylation profile of genes in determining risk of disease)

=> d his full

(FILE 'HOME' ENTERED AT 10:20:41 ON 24 SEP 2009)

FILE 'REGISTRY' ENTERED AT 10:21:27 ON 24 SEP 2009
L1 STRUCTURE UPLOADED
D
L2 0 SEA SSS SAM L1
L3 5 SEA SSS FUL L1
D QUE L3 STAT
L4 0 SEA ABB=ON PLU=ON L3 AND CHOLINE

FILE 'CAPLUS' ENTERED AT 10:22:47 ON 24 SEP 2009
L5 10 SEA ABB=ON PLU=ON L3
D 1-10 BIB ABS HITSTR

```
                E BROOK CHRIS/AU
L6           36 SEA ABB=ON  PLU=ON  ("BROOK CHRIS"/AU OR "BROOK CHRIS B"/AU OR
                "BROOK CHRISTOPHER S"/AU OR "BROOK CHRISTOPHER W"/AU)
                E PING LI/AU
L7           11 SEA ABB=ON  PLU=ON  ("PING LI JEN"/AU OR "PING LI JEN J"/AU)
L8           45 SEA ABB=ON  PLU=ON  L6 OR L7
L9            1 SEA ABB=ON  PLU=ON  L8 AND CHOLINE
                D QUE L9 STAT
                D BIB ABS
L10          11 SEA ABB=ON  PLU=ON  (THROMBOPOIETIN OR TPO) AND CHOLINE
L11          10 SEA ABB=ON  PLU=ON  L10 NOT L9
                D 1-10 BIB ABS KWIC


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   23 SEP 2009  HIGHEST RN 1186189-89-8
     DICTIONARY FILE UPDATES:  23 SEP 2009  HIGHEST RN 1186189-89-8

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/support/stngen/stndoc/properties.html

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 24 Sep 2009  VOL 151 ISS 13
     FILE LAST UPDATED: 23 Sep 2009  (20090923/ED)
     REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Jun 2009
     USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Jun 2009

     CAplus now includes complete International Patent Classification (IPC)
     reclassification data for the third quarter of 2009.

     CAS Information Use Policies apply and are available at:

     http://www.cas.org/legal/infopolicy.html
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	122.60	314.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-17.22	-17.22

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:31:21 ON 24 SEP 2009